CN112552293A - 一种protac小分子化合物及其应用 - Google Patents
一种protac小分子化合物及其应用 Download PDFInfo
- Publication number
- CN112552293A CN112552293A CN202011016521.8A CN202011016521A CN112552293A CN 112552293 A CN112552293 A CN 112552293A CN 202011016521 A CN202011016521 A CN 202011016521A CN 112552293 A CN112552293 A CN 112552293A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- cycloalkyl
- compound
- group
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 122
- 108010026668 snake venom protein C activator Proteins 0.000 title description 2
- 238000011865 proteolysis targeting chimera technique Methods 0.000 title 1
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 title 1
- -1 stereoisomer Chemical class 0.000 claims abstract description 89
- 150000003839 salts Chemical class 0.000 claims abstract description 54
- 239000012453 solvate Substances 0.000 claims abstract description 43
- 239000000651 prodrug Substances 0.000 claims abstract description 40
- 229940002612 prodrug Drugs 0.000 claims abstract description 40
- 150000002148 esters Chemical class 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 13
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 7
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 7
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims abstract description 4
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 131
- 150000003254 radicals Chemical class 0.000 claims description 85
- 229910052736 halogen Inorganic materials 0.000 claims description 59
- 150000002367 halogens Chemical class 0.000 claims description 59
- 125000004432 carbon atom Chemical group C* 0.000 claims description 49
- 239000003446 ligand Substances 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 44
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 35
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 claims description 27
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims description 24
- 102100032783 Protein cereblon Human genes 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 24
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 229940125962 HPK1 kinase inhibitor Drugs 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 150000002576 ketones Chemical class 0.000 claims description 9
- 150000003951 lactams Chemical class 0.000 claims description 9
- 150000002596 lactones Chemical class 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 8
- 208000026278 immune system disease Diseases 0.000 claims description 7
- 238000009169 immunotherapy Methods 0.000 claims description 7
- 125000005647 linker group Chemical group 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 102100028193 Mitogen-activated protein kinase kinase kinase kinase 3 Human genes 0.000 claims description 6
- 229910004749 OS(O)2 Inorganic materials 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 6
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 5
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 5
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 5
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 5
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 5
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 5
- 102000017578 LAG3 Human genes 0.000 claims description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 5
- 229940044665 STING agonist Drugs 0.000 claims description 5
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 5
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 5
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 5
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 5
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 5
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 238000002619 cancer immunotherapy Methods 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010007275 Carcinoid tumour Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims description 3
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004064 acoustic neuroma Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 210000003445 biliary tract Anatomy 0.000 claims description 3
- 201000000053 blastoma Diseases 0.000 claims description 3
- 208000002458 carcinoid tumor Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 3
- 201000008184 embryoma Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 3
- 201000000052 gastrinoma Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 206010024627 liposarcoma Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 206010027191 meningioma Diseases 0.000 claims description 3
- 208000007538 neurilemmoma Diseases 0.000 claims description 3
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims description 3
- 201000002628 peritoneum cancer Diseases 0.000 claims description 3
- 229960000688 pomalidomide Drugs 0.000 claims description 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000003804 salivary gland carcinoma Diseases 0.000 claims description 3
- 206010039667 schwannoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 210000002437 synoviocyte Anatomy 0.000 claims description 3
- 229960003433 thalidomide Drugs 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 101000573441 Homo sapiens Misshapen-like kinase 1 Proteins 0.000 claims description 2
- 101001059990 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 claims description 2
- 101001059989 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 3 Proteins 0.000 claims description 2
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 claims description 2
- 101001059982 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 5 Proteins 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 102100026287 Misshapen-like kinase 1 Human genes 0.000 claims description 2
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 claims description 2
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 claims description 2
- 102100028195 Mitogen-activated protein kinase kinase kinase kinase 5 Human genes 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 229910019999 S(O)2O Inorganic materials 0.000 claims description 2
- 229910007157 Si(OH)3 Inorganic materials 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229960004942 lenalidomide Drugs 0.000 claims description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 8
- 101100177670 Caenorhabditis elegans hpk-1 gene Proteins 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 204
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 147
- 238000006243 chemical reaction Methods 0.000 description 117
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 83
- 238000001035 drying Methods 0.000 description 71
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 64
- 239000012467 final product Substances 0.000 description 59
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- 238000010898 silica gel chromatography Methods 0.000 description 51
- 238000003756 stirring Methods 0.000 description 50
- 239000012074 organic phase Substances 0.000 description 48
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 46
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 44
- 239000012043 crude product Substances 0.000 description 44
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 36
- 238000010438 heat treatment Methods 0.000 description 36
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 33
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
- 238000010790 dilution Methods 0.000 description 29
- 239000012895 dilution Substances 0.000 description 29
- 239000003208 petroleum Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 238000000967 suction filtration Methods 0.000 description 23
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- 239000002253 acid Substances 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- 238000006731 degradation reaction Methods 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
- 230000015556 catabolic process Effects 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 229940125904 compound 1 Drugs 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 15
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 12
- 239000013557 residual solvent Substances 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 238000001816 cooling Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 125000006413 ring segment Chemical group 0.000 description 10
- 239000012286 potassium permanganate Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 108091005625 BRD4 Proteins 0.000 description 8
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000017854 proteolysis Effects 0.000 description 7
- 229960003010 sodium sulfate Drugs 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 101710144521 Mitogen-activated protein kinase kinase kinase kinase 3 Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- DOMTZTVJNZKUNX-UHFFFAOYSA-N tert-butyl 3-aminopropanoate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)CCN DOMTZTVJNZKUNX-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 3
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- WJVQJXVMLRGNGA-UHFFFAOYSA-N 5-bromopentan-1-ol Chemical compound OCCCCCBr WJVQJXVMLRGNGA-UHFFFAOYSA-N 0.000 description 2
- FCMCSZXRVWDVAW-UHFFFAOYSA-N 6-bromo-1-hexanol Chemical compound OCCCCCCBr FCMCSZXRVWDVAW-UHFFFAOYSA-N 0.000 description 2
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 description 2
- MMXRRNUXCHUHOE-UHFFFAOYSA-N 7-bromoheptan-1-ol Chemical compound OCCCCCCCBr MMXRRNUXCHUHOE-UHFFFAOYSA-N 0.000 description 2
- GMXIEASXPUEOTG-UHFFFAOYSA-N 8-bromooctan-1-ol Chemical compound OCCCCCCCCBr GMXIEASXPUEOTG-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100028907 Cullin-4A Human genes 0.000 description 2
- 101710159242 Cullin-4A Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 2
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 229950000080 birabresib Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- UZKBSZSTDQSMDR-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]piperazine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)N1CCNCC1 UZKBSZSTDQSMDR-UHFFFAOYSA-N 0.000 description 1
- LGZMUUBPTDRQQM-UHFFFAOYSA-N 10-Bromo-1-decanol Chemical compound OCCCCCCCCCCBr LGZMUUBPTDRQQM-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- DFXFQWZHKKEJDM-UHFFFAOYSA-N 2-(4-bromobutoxy)oxane Chemical compound BrCCCCOC1CCCCO1 DFXFQWZHKKEJDM-UHFFFAOYSA-N 0.000 description 1
- LKEGXJXRNBALBV-PMCHYTPCSA-N 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-[4-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]butyl]acetamide Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NCCCCNC(=O)COC(C=1C2=O)=CC=CC=1C(=O)N2C1CCC(=O)NC1=O LKEGXJXRNBALBV-PMCHYTPCSA-N 0.000 description 1
- ZXFLMSIMHISJFV-UHFFFAOYSA-N 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]acetic acid Chemical compound CC(C)(C)OC(=O)N1CCC(CC(O)=O)CC1 ZXFLMSIMHISJFV-UHFFFAOYSA-N 0.000 description 1
- SMRZYHJYSHNQSG-UHFFFAOYSA-N 2-azido-1,1-diethoxyethane Chemical compound CCOC(OCC)CN=[N+]=[N-] SMRZYHJYSHNQSG-UHFFFAOYSA-N 0.000 description 1
- SNIHFSORRRKZHM-UHFFFAOYSA-N 3-(2-iodoethoxy)prop-1-yne Chemical compound ICCOCC#C SNIHFSORRRKZHM-UHFFFAOYSA-N 0.000 description 1
- YCPULGHBTPQLRH-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;hydron;chloride Chemical compound Cl.NC1CCC(=O)NC1=O YCPULGHBTPQLRH-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- CCTOEAMRIIXGDJ-UHFFFAOYSA-N 4-hydroxy-2-benzofuran-1,3-dione Chemical compound OC1=CC=CC2=C1C(=O)OC2=O CCTOEAMRIIXGDJ-UHFFFAOYSA-N 0.000 description 1
- USJDOLXCPFASNV-UHFFFAOYSA-N 9-bromononan-1-ol Chemical compound OCCCCCCCCCBr USJDOLXCPFASNV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 1
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010088874 Cullin 1 Proteins 0.000 description 1
- 102100039195 Cullin-1 Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102000012698 DDB1 Human genes 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100170004 Dictyostelium discoideum repE gene Proteins 0.000 description 1
- 101100170005 Drosophila melanogaster pic gene Proteins 0.000 description 1
- 102100023877 E3 ubiquitin-protein ligase RBX1 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 1
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 1
- 101100275693 Homo sapiens CRBN gene Proteins 0.000 description 1
- 101001111722 Homo sapiens E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 1
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 1
- 101000574654 Homo sapiens GTP-binding protein Rit1 Proteins 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000007849 Lepidium sativum Nutrition 0.000 description 1
- 244000211187 Lepidium sativum Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229940124614 TLR 8 agonist Drugs 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- DPRMFUAMSRXGDE-UHFFFAOYSA-N ac1o530g Chemical compound NCCN.NCCN DPRMFUAMSRXGDE-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical class O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 102000022604 damaged DNA binding proteins Human genes 0.000 description 1
- 108091013406 damaged DNA binding proteins Proteins 0.000 description 1
- 101150077768 ddb1 gene Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940056729 sodium sulfate anhydrous Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Description
技术领域
本发明属于生物医药领域,具体涉及一种PROTAC小分子化合物及其应用。
背景技术
蛋白降解靶向嵌合体(PROTAC)技术源于科学家发现了泛素(Ubiquitin,Ub)调节的蛋白降解过程。真核生物细胞中一直在努力维持适当的蛋白水平,每一时刻它们都在生成和降解成千上万种蛋白。维持蛋白平衡的关键因子是一种称为泛素的小蛋白分子。当它被链接到蛋白上后,会导致这些蛋白被运送到蛋白酶体中进行降解。
蛋白靶向降解(Targeted protein degradation)是药物研发领域的一个新兴方向。蛋白靶向降解药物力图将小分子设计成为一种新型药物,传统小分子的作用是阻断蛋白的功能,而蛋白靶向降解剂的作用是通过将这些蛋白送入蛋白酶体(proteasome)将它们完全降解。
2010年,Handa及其同事的研究发现E3连接酶Cereblon(CRBN)为沙利度胺蛋白质的主要靶点。考虑到邻苯二甲酰亚胺结合CRBN的能力,Crews实验室和其他人试图利用邻苯二甲酰亚胺作为E3连接酶募集配体来劫持CRBN以降解目标蛋白质。小分子BRD4结合部分(OTX015)与Pomalidomide的缀合产生能够在皮摩尔效能下降解表观遗传调节物 BRD4的PROTAC。与BRD4抑制剂JQ1和OTX015相比,基于CRBN的PROTAC通过抵消已知与BRD4抑制相关的反馈BRD4表达增加,从而能够更持久地抑制c-myc的表达水平。在细胞水平,这种持续抑制导致了对Burkitt's淋巴瘤细胞系优异的抗增殖和凋亡作用。在一个研究中,BRD4抑制剂JQ1与沙利度胺衍生物结合,由此产生的PROTAC,称为dBET1,能够在低纳摩尔浓度下诱导BRD4降解。对此PROTAC的蛋白质组学研究表明该化合物显着降低了c-myc、BRD2、BRD3和BRD4水平,同时具有较小的脱靶降解效应。
Cereblon是由人类CRBN基因编码的蛋白,CRBN同源基因是高度保守的,这表明它在生理学中的重要性。Cereblon与损伤DNA结合蛋白1(DDB1)、Cullin-4A(CUL4A)以及Cullin-1调节器(ROC1)组成E3泛素连接酶复合体。该复合体能泛素化一系列蛋白,但具体机制尚不清楚。Cereblon泛素化靶蛋白导致成纤维细胞生长因子8(FGF8)和成纤维细胞生长因子10(FGF10)增多,说明泛素化酶复合体对于胚胎肢体生长十分重要。
造血干细胞激酶1(Hematopoietic progenitor kinase 1,HPK1)参与很多信号级联反应,包括生长因子信号、MAPK信号、细胞因子信号、凋亡信号、生长因子信号以及抗原受体信号等。HPK1激酶是JNK/SAPK信号通路的关键功能性活化因子,当被激活后,它可以选择性地激活C-Jun N-terminal kinase(JNK)的MAPK信号通路。HPK1激酶可作为免疫治疗的靶点,其被淋巴细胞抗原受体激活,并抑制AP-1,而AP-1在肿瘤形成及发展过程中在促进细胞增殖、抑制分化、促进肿瘤细胞的侵袭和转移等过程中发挥作用。而针对性的破坏HPK1激酶的等位基因可以使T细胞在TCR应答中提高Th1细胞因子的产生。
本发明设计的一种蛋白降解靶向嵌合体可以对HPK1进行泛素化标记,诱导蛋白降解,效果优于HPK1激酶抑制剂单独作用,即可利用小剂量药物抑制HPK1蛋白表达。在相同治疗效果前提下,使用药物剂量更少,毒副作用更小。
发明内容
本发明的目的是提供一种Cereblon配体诱导HPK1降解的蛋白降解靶向嵌合体,及所述蛋白降解靶向嵌合体与其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物在***,炎症,免疫等疾病中的应用。
本发明的目的是通过以下技术方案实现的:
本发明提供一种通式为Ⅰ的化合物:
其中,MAP4Ks家族抑制剂选自:HPK1抑制剂、MAP4K2抑制剂、MAP4K3抑制剂、MAP4K4抑制剂、MAP4K5抑制剂、MAP4K6抑制剂;优选的,MAP4Ks家族抑制剂选自: HPK1(MAP4K1)抑制剂;
其中q选自1-5之间的整数;
Cereblon蛋白配体为E3泛素连接酶复合体中Cereblon蛋白的小分子配体;
L是Cereblon蛋白配体与HPK1抑制剂之间的连接基团;
Cereblon蛋白配体的连接位点和连接数量影响化合物活性,在本申请中,q选自1-5 之间的整数,优选的,q选自1-3之间的整数,如1、2、3。
Cereblon蛋白配体是指E3泛素连接酶复合体中Cereblon蛋白的小分子配体,所述Cereblon蛋白配体选自:酰胺类化合物、邻苯二酰亚胺类化合物、沙利度胺或其衍生物、来那度胺或其衍生物、泊马度胺或其衍生物。
优选的,所述Cereblon蛋白配体的通式如下所示:
其中,C1、C2、C3、C4独立的选自C或N;优选的,C1、C2、C3、C4选自C;当C1为C时,C2、C3、C4至少一个为N;当C2为C时,C1、C3、C4至少一个为N;当C3为C 时,C1、C2、C4至少一个为N;当C4为C时,C1、C2、C3至少一个为N。
T选自O或S;
G、Z独立的选自H、-OH、C1-10直链/支链烷基、C3-10环烃基、含O杂环烃基、含N 杂环烃基、含S杂环烃基。
优选的,C1、C2、C3、C4选自C;
T选自O;
G、Z独立的选自-H、-CH3、-CH2CH3。
在本发明的优选实施方式中,所述Cereblon蛋白配体结构式如下:
L是Cereblon蛋白配体与HPK1抑制剂之间的连接基团,Cereblon蛋白配体与HPK1抑制剂通过共价键相连,所述连接基团为-A1-A2……-At-,
A1,A2……At独立的选自:
CRL1RL2、O、S、S=O、S(=O)2、-S(O)2O、-OS(O)2、OS(O)2O、NRL3、S(=O)2NRL3、 S(=O)NRL3、C(=O)NRL3、OC(O)NRL3、NRL3C(=O)、NRL3C(=O)NRL4、NRL3S(=O)2NRL4、 C(=O)、CRL1=CRL2、C=C、C≡C、SiRL1RL2、P(=O)RL1、P(=O)ORL1、NRL3C(=N-CN)NRL4、 NRL3C(=N-CN)、NRL3C(=C-NO2)NRL4、C3-11环烃基、C3-11杂环烃基、琥珀酰亚胺基、-CH2CH2O-、-OCH2CH2-、或不存在,其中,所述的环烃基、杂环烃基中任意氢原子可被1-6个RL1或RL2取代;
当A1,A2……At为CRL1RL2或SiRL1RL2时,RL1、RL2独立地可以与其它A连接形成环烃基或杂环烃基,优选的,所述的环烃基或杂环烃基任选地被1-11个RL5基团取代;
RL1、RL2、RL3、RL4、RL5独立的选自H、卤素、C1-8烷基、O(C1-8烷基)、S(C1-8烷基)、 NH(C1-8烷基)、N(C1-8烷基)2、C3-11环烃基、C3-11杂环烃基、O(C1-8环烃基)、S(C1-8环烃基)、 NH(C1-8环烃基)、N(C1-8环烃基)(C1-8烷基)、OH、NH2、SH、SO2(C1-8烷基)、P(=O)(OC1-8烷基)(C1-8烷基)、P(=O)(OC1-8烷基)2、C1-8炔基、CH=CH(C1-8烷基)、C(C1-8烷基)=CH(C1-8烷基)、C(C1-8烷基)=C(C1-8烷基)2、Si(OH)3、Si(C1-8烷基)3、Si(OH)(C1-8烷基)2、C(=O)(C1-8烷基)、CO2H、CN、CF3、CHF2、CH2F、NO2、SF5、SO2NH(C1-8烷基)、SO2N(C1-8烷基)2、 S(=O)N(C1-8烷基)2、C(=O)NH(C1-8烷基)、C(=O)N(C1-8烷基)2、N(C1-8烷基)C(=O)NH(C1-8烷基)、N(C1-8烷基)C(=O)N(C1-8烷基)2、NHC(=O)NH(C1-8烷基)、NHC(=O)N(C1-8烷基)2、 NHC(=O)NH2、N(C1-8烷基)SO2NH(C1-8烷基)、N(C1-8烷基)SO2N(C1-8烷基)2、NHSO2NH(C1-8烷基)、NHSO2N(C1-8烷基)2或NHSO2NH2;
X3选自-O-、-S-、-NR-、-CHR-;
R选自H或被1个或2个-OH取代的C1-3烷基;
i选自1-6之间的整数;
Y选自-O-、-S-、-NR-或不存在;
t选自1-100之间的整数,优选的,t选自1-50的整数。
其中,s选自1-6之间的整数;
i选自1-6之间的整数;
n选自1-10之间的整数,优选为1-4之间的整数;
m选自0-10之间的整数,优选为2-7之间的整数;
X1选自-O-、-S-、-NR-;
X2选自-O-、-S-、NR-、-S(O)-、-S(O)2O、-OS(O)2-、-OS(O)2O-。
在本发明的另一个实施方式中,所述连接基团选自:
其中,Ar选自含N六元芳香基;
g选自0或1;
n选自1-10之间的整数,优选为1-4之间的整数;
m选自1-10之间的整数;优选为2-7之间的整数;
k选自1-10之间的整数;优选为1-4之间的整数;
p选自1-10之间的整数;优选为1-2之间的整数。
在本发明的优选实施方公式中,所述L连接基团的结构如下:
本发明所述的HPK1抑制剂的通式如下:
上述HPK1通式均有3个Cereblon蛋白配体的连接位点,可任意连接3个、2个或1 个Cereblon蛋白配体,其余连接位点用-R”’代替;R”’选自-H、卤素、-NO2、-CN、C1-5直链/支链烷基、C3-10环烃基、-N(C0-10烷基)(C0-10烷基)、-CF3、-OCF3、-OCHF2、-OCH2F 或-OC0-10烷基;优选的,R”’选自-H、卤素、C1-5直链/支链烷基、-N(C0-10烷基)(C0-10烷基);更优选的,R”’选自-H、卤素。
优选的,①位、②位和③位均是Cereblon蛋白配体的连接位点,或者,①位和②位是Cereblon 蛋白配体的连接位点,③位连接R”’,或者,②位和③位是Cereblon蛋白配体的连接位点,①位连接R”’,或者,①位和③位是Cereblon蛋白配体的连接位点,②位连接R”’,或者,①位是Cereblon蛋白配体的连接位点,②位和③位连接R”’,或者,②位是Cereblon蛋白配体的连接位点,①位和③位连接R”’,或者,③位是Cereblon蛋白配体的连接位点,①位和②位连接R”’。
最优选的,①位、②位和③位连接位点均连接Cereblon蛋白配体。
对于上述HPK1抑制剂的通式,A选自C或N;B选自C或N。
所述Q选自O或S;x和z独立的选自0-6间的整数;y选自0或1。
优选的,x和z独立的选自0-2间的整数,如0、1或2。
优选的,所述HPK1抑制剂结构式为:
所述R0独立的选自:-H、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基或C3-10环烃基。
优选的,所述R0独立的选自:C1-5直链/支链烷基或-N(C0-10烷基)(C0-10烷基)。
在本发明的优选实施方式中,R0独立的选自:-CH3、-CH2CH3或-NH2。
所述R1选自-O杂环烷基、-N杂环烷基、C1-10直链/支链烷基、C3-10环烷基、-OC0-10烷基、-N(C0-10烷基)(C0-10烷基)、-SO2(C0-10烷基)、-O(C0-10烷基)、-O-苯基、-S(C0-10烷基)、 -N杂环芳香基、-O杂环芳香基或-S杂环芳香基,其中C原子或杂原子上的H可被C1-3直链烷基、-N(C0-10烷基)(C0-10烷基)、-CF3取代。
优选的,所述R1选自:-O杂环烷基或-N杂环烷基、-SO2(C0-3烷基)、-O-苯基、-S(C0-4烷基)、C3-6环烷基或C3-5直链/支链烷基,其中C原子或杂原子上的H可被-CH3、-NH2、 -CF3取代。
在本发明的优选实施方式中,所述R1选自:
所述R2选自:-H、卤素、-NO2、-CN、C1-5直链/支链烷基、C3-10环烃基、-N(C0-10烷基)(C0-10烷基)、-CF3、-OCF3、-OCHF2、-OCH2F或-OC0-10烷基。
优选的,所述R2选自:-NO2、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基或-OCF3。
在本发明的优选实施方式中,所述R2选自:-NH2或-NO2。
当B为N时,R3不存在;当B为C时,所述R3选自:-H、卤素、-OC0-10烷基、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)或C3-10环烃基。
优选的,所述R3选自:-H、卤素、-OC0-10烷基、C1-10直链/支链烷基。
在本发明的优选实施方式中,所述R3选自:-H、-F或-OCH3。
所述R4选自:-H、卤素、-OC0-10烷基、-CN、C3-10环烃基、-C≡C-R10、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-O杂环烃基或-N杂环烃基。
优选的,所述R4选自:-H、卤素、-OC0-10烷基、-CN、C3-10环烷基或-C≡C-R10。
所述R11、R12独立的选自:-H、-CF3、-CHF2H、-CH2F、C1-10直链/支链烷基、-CH= C(C0-10烷基)(C0-10烷基)、-C≡C(C0-10烷基)、C3-10环烷基、芳香性五元环基团或芳香性六元环基团,或R11、R12与R11和R12之间的碳原子形成C3-8环烷基或含-O、-S的C3-8杂环烷基,C4-9稠环烷基、C3-7环内酰胺、C3-7环内酯、C3-7环酮,其中C原子上的H可被烷基或卤素取代。
优选的,所述R11、R12独立的选自:-H、-CF3、-CHF2H、-CH2F、C1-10直链/支链烷基、 -CH=C(C0-10烷基)(C0-10烷基)、C3-10环烷基或芳香性六元环基团,或R11、R12与R11和R12之间的碳原子形成C3-8环烷基、C4-7稠环烷基、C3-7环内酰胺、C3-7环内酯、C3-7环酮,其中C原子上的H可被烷基或-F取代。
更优选的,所述R11、R12独立的选自:-H、-CF3、-CHF2H、-CH2F、C1-5直链/支链烷基、-CH=CH(C0-10烷基)、C3-10环烷基或芳香性六元环基团,或R11、R12与R11和R12之间的碳原子形成C3-6环烷基、C4-6稠环烷基、C3-7环内酰胺、C3-7环内酯、C3-7环酮,其中C 原子上的H可被烷基或-F取代。
R5选自:-H、卤素、-CN、-OC0-10烷基、C1-10直链/支链烷基、含O或N的杂烷基、 -N(C0-10烷基)(C0-10烷基)、C3-10环烃基、-C≡C-R10、-O杂环烃基或-N杂环烃基,其中C原子上的H可被以下基团取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、-N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、-OCH2F、-OCHF2、-OCF3、C1-10直链/ 支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、C3-10环烃基、-O杂环烷基、-N杂环烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基。
优选的,所述R5选自:-H、卤素、C3-6环烷基、-OC0-5烷基、C1-5直链/支链烷基、含 O或N的C1-5直链/支链烷基,其中C原子上的H可被-F取代。
更优选的,所述R5选自:-H、卤素、-OC0-3烷基、C1-3直链/支链烷基、含N的C1-3直链/支链烷基,其中C原子上的H可被-F取代。
在本发明的优选实施方式中,所述R5选自:-H、-F、-Cl、-CH3、-CH2NH2、-CN、-OCH3。
R8和R9独立的选自:-H、卤素、C1-10直链/支链烷基。
优选的,所述R8和R9独立的选自:-H、C1-10直链/支链烷基。
更优选的,所述R8和R9独立的选自:-H、C1-3直链/支链烷基。
在本发明的优选实施方式中,所述R8和R9独立的选自:-H或-CH3。
A'选自C或N;B1、B2、B3、B4或B5独立的选自C或N;
优选的,所述B1、B2、B3、B4或B5为C,或所述B1、B2、B3、B4或B5中至少一个为 N;
更优选的,所述的B2为C,所述的B1、B3、B4或B5中至少一个为N。在本发明的一个实施方式中,所述的B2为C,所述的B1为N;所述的B2为C,所述的B3为N;所述的 B2为C,所述的B4为N;所述的B2为C,所述的B5为N。在本发明的另一个实施方式中,所述的B2为C,B3和B4为N或者B3和B5中为N。
Q'选自O或S;x'和z'独立的选自0-6间的整数;y'选自0或1;
优选的,x'和z'独立的选自0-2间的整数,如0、1或2。
优选的,所述HPK1抑制剂结构式为:
所述R0'独立的选自:-H、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基或C3-10环烃基。
优选的,所述R0'独立的选自:C1-5直链/支链烷基或-N(C0-10烷基)(C0-10烷基)。
在本发明的优选实施方式中,R0'独立的选自:-CH3、-CH2CH3或-NH2。
所述R1'选自:-O杂环烷基、-N杂环烷基、C1-10直链/支链烷基、C3-10环烃基、-OC0-10烷基、-N(C0-10烷基)(C0-10烷基)、-SO2(C0-10烷基)、-O(C0-10烷基)、-O-苯基、-S(C0-10烷基)、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基,其中C原子或杂原子上的H可被C1-3直链烷基、-N(C0-10烷基)(C0-10烷基)、-CF3取代。
优选的,所述R1'选自:-O杂环烷基或-N杂环烷基、-SO2(C0-3烷基)、-O-苯基、-S(C0-4烷基)、C3-6环烷基或C3-5直链/支链烷基,其中C原子或杂原子上的H可被-CH3、-NH2、 -CF3取代。
所述R2'选自:-H、卤素、-NO2、-CN、C1-5直链/支链烷基、C3-10环烃基、-N(C0-10烷基)(C0-10烷基)、-CF3、-OCF3、-OCHF2、-OCH2F或-OC0-10烷基。
优选的,所述R2'选自:-NO2、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基或-OCF3。
在本发明的优选实施方式中,所述R2'选自:-NH2或-NO2。
当B1、B2、B3、B4或B5为N时,其所对应的R3'、R4'、R5'不存在;当B1、B2、 B3、B4或B5为C时,所述R3'、R4'、R5'独立的选自:-H、卤素、-CN、-OC0-10烷基、 C1-10直链/支链烷基、含O或N的杂烷基、-N(C0-10烷基)(C0-10烷基)、C3-10环烃基、-C≡C-R10'、 -O杂环烃基、-N杂环烃基,或R5'和R4'、R4'和R3'与其之间的碳原子形成C3-8环烃基或含-O-、-S-的C3-8杂环烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基、苯基,其中C原子上的H可被以下基团取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、-N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、-OCH2F、-OCHF2、-OCF3、 C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、C3-10环烃基、-O杂环烷基、 -N杂环烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基。
优选的,所述R3'选自:-H、卤素、-OC0-10烷基、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)或C3-10环烷基。
更优选的,所述R3'选自:-H、卤素、-OC0-10烷基、C1-10直链/支链烷基。
在本发明的优选实施方式中,所述R3'选自:-H、-F或-OCH3。
优选的,所述R4'选自:-H、卤素、-OC0-10烷基、-CN、C3-10环烷基、-C≡C-R10'、 C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-O杂环烷基或-N杂环烷基。
更优选的,所述R4'选自:-H、卤素、-OC0-10烷基、-CN、C3-10环烷基或-C≡C-R10'。
优选的,R5'独立的选自:-H、卤素、-CN、-OC0-10烷基、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、C3-10环烷基、-C≡C-R10'、-O杂环烷基或-N杂环烷基、含O或N的 C1-5直链/支链烷基,其中C原子上的H可被-F取代,
更优选的,所述R5'独立的选自:-H、卤素、C1-3直链/支链烷基、-OC0-3烷基、含N 的C1-3直链/支链烷基,其中C原子上的H可被-F取代。
在本发明的优选实施方式中,所述R5'选自:-H、-F、-Cl、-CH3、-CH2NH2、-CN、 -OCH3。
所述R11'、R12'独立的选自:-H、-CF3、-CHF2H、-CH2F、C1-10直链/支链烷基、-CH =C(C0-10烷基)(C0-10烷基)、-C≡C(C0-10烷基)、C3-10环烃基、芳香性五元环基团或芳香性六元环基团,或R11、R12与R11和R12之间的碳原子形成C3-8环烷基或含-O、-S的C3-8杂环烷基、C4-9稠环烷基、C5-10螺环烷基、C4-9桥环烷基、C3-7环内酰胺、C3-7环内酯、C3-7环酮,其中C原子上的H可被以下基团取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、-N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、-OCH2F、-OCHF2、-OCF3、 C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、C3-10环烃基、-O杂环烷基、 -N杂环烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基,其中所述烷基部分可被一个或多个以下基团任意取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、-N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、-OCH2F、-OCHF2、-OCF3、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基。
优选的,所述R11'、R12'独立的选自:-H、-CF3、-CHF2H、-CH2F、C1-10直链/支链烷基、-CH=C(C0-10烷基)(C0-10烷基)、C3-10环烷基或芳香性六元环基团,或R11、R12与R11和R12之间的碳原子形成C3-8环烷基、C4-7稠环烷基、C5-9螺环烷基、C4-9桥环烷基、C3-7环内酰胺、C3-7环内酯、C3-7环酮,其中C原子上的H可被以下基团取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、-N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、 -OCH2F、-OCHF2、-OCF3、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、 C3-10环烷基、-O杂环烷基、-N杂环烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基,其中所述烷基部分可被一个或多个以下基团任意取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、 -N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、 -N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、-OCH2F、-OCHF2、 -OCF3、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基。
更优选的,所述R11'、R12'独立的选自:-H、-CF3、-CHF2H、-CH2F、C1-5直链/支链烷基、-CH=CH(C0-10烷基)、C3-10环烷基或芳香性六元环基团,或R11'、R12'与R11'和R12'之间的碳原子形成C3-6环烷基、C4-6稠环烷基、C5-8螺环烷基、C4-8桥环烷基、C3-7环内酰胺、C3-7环内酯、C3-7环酮,其中C原子上的H可被以下基团取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、-N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、-OCH2F、-OCHF2、-OCF3、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、 C3-10环烷基、-O杂环烷基、-N杂环烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基,其中所述烷基部分可被一个或多个以下基团任意取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、 -N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、 -N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、-OCH2F、-OCHF2、 -OCF3、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基。
在本发明的优选实施方式中,所述R11'、R12'独立的选自:-H、-CF3、-CHF2、-CH2F、-CH3、-CH2CH3、-CH=CH2、 或R11'、R12'与R11'和R12'之间的碳原子形成
R8'和R9'独立的选自:-H、卤素、C1-10直链/支链烷基。
优选的,所述R8'和R9'独立的选自:-H、C1-10直链/支链烷基。
更优选的,所述R8'和R9'独立的选自:-H、C1-3直链/支链烷基。
在本发明的优选实施方式中,所述R8'和R9'独立的选自:-H或-CH3。
在本发明的优选实施方式中,HPK1抑制剂具体结构如下:
本发明所述的HPK1抑制剂还包括现有技术公开的化合物,包括如下通式:
其中,R35、R36、R38、R39选自C1-10直链 /支链烷基、-CON(C0-10烷基)-、-CO(C0-10烷基)-、C3-10环烃基、-O杂环烷基、-N杂环烷基、苯基、-N杂环芳香基、-O杂环芳香基,R37与相连的N原子及N相邻的C原子形成5-8 元环内酰胺。
优选的,R35、R36、R38、R39选自-CO(C0-10烷基)-、-N杂环烷基、苯基、-N杂环芳香基,R37与相连的N原子及N相邻的C原子形成7元环内酰胺。
更优选的,所述HPK1抑制剂通式如下:
①位和②位是Cereblon蛋白配体的连接位点,或者,①位是Cereblon蛋白配体的连接位点,②位连接R”’,或者,②位是Cereblon蛋白配体的连接位点,①位连接R”’;
其中,R13-R34独立的选自:-H、卤素、-CN、-OC0-10烷基、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、C3-10环烃基、-O杂环烷基、-N杂环烷基、-S杂环烷基、苯基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基。
优选的,所述R13-R34独立的选自:-H、卤素、-CN、C1-4直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、C3-5环烷基。
优选的,所述HPK1抑制剂结构式如下:
在本发明的优选实施方式中,所述化合物具体结构式如下:
本发明所述的通式为Ⅰ的化合物还包括其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物。
本发明提供一种药物组合物,所述药物组合物包含通式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物,还包括药剂学上可接受的辅料,所述辅料选自:填充剂、粘合剂、润滑剂。优选的,所述药物组合物包含治疗有效量的通式Ⅰ的化合物。在某些实施方案中,所述药物组合物可单独使用,或与其他种类的药物制剂联合使用。
所述其他种类的药物制剂包括:PD-1、PD-L1、CTLA-4、TIM-3、TGF-β及其受体、LAG3拮抗剂或TLR4、TLR7、TLR8、TLR9、STING激动剂。
所述填充剂选自:乳糖、微晶纤维素、甲基纤维素、羟甲基纤维素钠、乙基纤维素、羟丙基纤维素、羟丙基甲基纤维素中的一种或两种以上的组合。
所述粘合剂选自:淀粉、糊精、纤维素衍生物、聚维酮、明胶、聚乙二醇、聚乙烯醇、蔗糖中的一种或两种以上的组合。
所述润滑剂选自:蒸馏水、乙醇、淀粉浆中的一种或两种以上的组合。
优选的,所述药物组合物还包括抗氧化剂、缓冲剂、抑菌剂,和使制剂与受试者血液等渗的溶质,以及含水和非水的无菌悬浮剂,其可包含助悬剂、增溶剂、增稠剂、稳定剂和防腐剂。
所述药物组合物适于胃肠给药或非胃肠给药,如通过静脉内、肌内、皮内和皮下途径给药。
所述药物组合物可以制备成以下形式的药物制剂:针剂、糖浆剂、酏剂、悬浮剂、粉剂、颗粒剂、片剂、胶囊、锭剂、霜剂、膏剂、洗液剂、凝胶剂、乳剂等。
在制备针剂时,可以使用本领域内任何常用的载体,例如:水、乙醇、丙二醇、乙氧基化的异硬脂醇、聚乙氧基化的异硬脂醇和聚乙烯脱水山梨醇的脂肪酸酯等。此外,还可以加入常用的溶解剂和缓冲剂等。
本发明提供一种通式Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物在制备抑制丝氨酸/苏氨酸激酶家族的药物中的应用,优选的,在制备抑制造血干细胞激酶1的药物中的应用。
本发明提供一种通式Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物在制备治疗与丝氨酸/苏氨酸激酶家族相关的疾病的药物中的应用,优选的,与造血干细胞激酶1(HPK1)相关的疾病的药物中的应用。
所述的与造血干细胞激酶1(HPK1)相关的疾病选自:炎症、免疫疾病、癌症。
所述免疫疾病选自:红斑狼疮、血管球性肾炎、类风湿性关节炎、牛皮癣、炎症性肠病和自身免疫糖尿病。
所述癌症选自:淋巴瘤、母细胞瘤、髓母细胞瘤、视网膜母细胞瘤、肉瘤、脂肪肉瘤、滑膜细胞肉瘤、神经内分泌肿瘤、类癌肿瘤、胃泌素瘤、胰岛细胞癌、间皮瘤、神经鞘瘤、听神经瘤、脑膜瘤、腺癌、黑素瘤、白血病或淋巴样恶性肿瘤、鳞状细胞癌、上皮鳞状细胞癌、肺癌、小细胞肺癌、非小细胞肺癌、腺癌肺癌、肺鳞癌、腹膜癌、肝细胞癌、胃癌、肠癌、胰腺癌、成胶质细胞瘤、子***、卵巢癌、肝癌、膀胱癌、肝癌、乳腺癌、转移性乳腺癌、结肠癌、直肠癌、结肠直肠癌、子宫癌、唾液腺癌、肾癌、***癌、外阴癌、甲状腺癌、肝癌、***癌、***癌、梅克尔细胞癌、食管癌、胆道肿瘤、头颈部癌和血液恶性肿瘤。
优选的,所述通式Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物可单独使用,或与其它种类的药物制剂和/或治疗方法联合使用。
所述其他种类的药物制剂选自:PD-1、PD-L1、CTLA-4、TIM-3、TGF-β及其受体、LAG3拮抗剂或TLR4、TLR7、TLR8、TLR9、STING激动剂。
所述其他种类的治疗方法选自:放射疗法、免疫疗法。
本发明提供一种通式为Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物在预防和/或治疗癌症、免疫疾病、炎症中的应用。
本发明提供一种通式为Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物在制备预防和/或治疗癌症、免疫疾病、炎症药物中的应用。
本发明还提供了通式Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物联合PD-1、PD-L1、CTLA-4、TIM-3、TGF-β及其受体、LAG3拮抗剂或TLR4、TLR7、TLR8、TLR9、STING激动剂在癌症免疫疗法中的应用。
本发明还提供了通式Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物与CAR-T免疫疗法相结合在癌症免疫疗法中的应用。
所述CAR-T免疫疗法是指:嵌合抗原受体T细胞免疫疗法,是目前较为有效的恶性肿瘤的治疗方式之一,其基本原理是利用病人自身的免疫细胞来清除癌细胞,属于一种细胞疗法。
本发明所述的癌症包括淋巴瘤、母细胞瘤、髓母细胞瘤、视网膜母细胞瘤、肉瘤、脂肪肉瘤、滑膜细胞肉瘤、神经内分泌肿瘤、类癌肿瘤、胃泌素瘤、胰岛细胞癌、间皮瘤、神经鞘瘤、听神经瘤、脑膜瘤、腺癌、黑素瘤、白血病或淋巴样恶性肿瘤、鳞状细胞癌、上皮鳞状细胞癌、肺癌、小细胞肺癌、非小细胞肺癌、腺癌肺癌、肺鳞癌、腹膜癌、肝细胞癌、胃癌、肠癌、胰腺癌、成胶质细胞瘤、子***、卵巢癌、肝癌、膀胱癌、肝癌、乳腺癌、转移性乳腺癌、结肠癌、直肠癌、结肠直肠癌、子宫癌、唾液腺癌、肾癌、***癌、外阴癌、甲状腺癌、肝癌、***癌、***癌、梅克尔细胞癌、食管癌、胆道肿瘤、头颈部癌和血液恶性肿瘤。
本发明所述的药学上可接受的盐中包括酸加成盐和碱加成盐。
所述的酸加成盐包括但不限于来自无机酸诸如盐酸、硝酸、磷酸、硫酸、氢溴酸、氢碘酸和膦酸的盐,以及来自有机酸如脂肪族单羧酸和二羧酸、苯基取代的链烷酸、羟基链烷酸、链烷二酸、芳香酸和脂肪族和芳香族磺酸的盐。因此,这些盐包括但不限于硫酸盐、焦硫酸盐、硫酸氢盐、亚硫酸盐、亚硫酸氢盐、硝酸盐、磷酸盐、磷酸一氢盐、磷酸二氢盐、偏磷酸盐、焦磷酸盐、盐酸盐、氢溴酸盐、碘酸盐、乙酸盐、丙酸盐、辛酸盐、异丁酸盐、乙二酸盐、丙二酸盐、琥珀酸盐、辛二酸盐、癸二酸盐、富马酸盐、马来酸盐、苦杏仁酸盐、苯甲酸盐、氯代苯甲酸盐、甲基苯甲酸盐、二硝基苯甲酸盐、酞酸盐、苯磺酸盐、甲苯磺酸盐、苯基乙酸盐、柠檬酸盐、乳酸盐、马来酸盐、酒石酸盐和甲磺酸盐,还包含氨基酸的盐如精氨酸盐、葡糖酸盐、半乳糖醛酸盐等。酸加成盐可以通过以常规方式使游离碱形式与足够量的所需酸接触形成盐的方式制备。可通过使盐形式与碱接触重新生成游离碱形式,并且以常规方式分离该游离碱。
本发明所述的碱加成盐是指与金属或者胺形成的盐,诸如碱金属和碱土金属的氢氧化物,或者与有机胺形成。用作阳离子的金属的例子包括但是不限于钠、钾、镁、和钙。适当的胺的例子包括但是不限于N,N′-二苄基乙二胺、氯普鲁卡因、胆碱、二乙醇胺、乙二胺(乙烷-1,2-二胺)、N-甲基葡糖胺和普鲁卡因。碱加成盐可通过以常规方式使游离酸形式与足够量的所需碱接触形成盐的方式制备。可通过使盐形式与酸接触重新生成游离酸形式,并且以常规方式分离游离酸。
本发明所述的立体异构体包括对映体、非对映体和几何异构体的形式存在。本发明的一些化合物具有环烃基,其可在超过一个碳原子上被取代,在这种情况下,其所有的几何形式,包括顺式和反式,及其混合物,都处在本发明的范围内。所述的环烃基包括脂环烃基和芳基,其中脂环烃基可以为非芳香的单环、稠环、桥环或螺环的饱和或不饱和的环状烃基,芳基如苯基、萘基、菲基、联苯基等。
本发明所述的溶剂化物是指本发明的化合物与一种或多种溶剂分子的物理结合。该物理结合包括各种程度的离子和共价键合,包括氢键合。在某些情况下,溶剂化物可被分离出来,例如当一个或多个溶剂分子掺入到结晶固体的晶格中。溶剂化物包括溶液相和可分离的溶剂化物。代表性的溶剂化物包括乙醇化物、甲醇化物等。
本发明所述的前药指适于对患者给药的无过分毒性、刺激性和***反应等的并且对其应用目的有效的式Ⅰ化合物形式,包括缩醛、酯和两性离子形式。前药在体内转化,如通过在血液中水解,得到上式的母体化合物。
本发明所述的术语C0-10烷基,C0烷基是指H,因此,C0-10烷基包括H、C1烷基、C2烷基、C3烷基、C4烷基、C5烷基、C6烷基、C7烷基、C8烷基、C9烷基、C10烷基。
本发明所述的术语C1-10直链/支链烷基,包括甲基、乙基、C3直链/支链烷基、C4直链/支链烷基、C5直链/支链烷基、C6直链/支链烷基、C7直链/支链烷基、C8直链/支链烷基、 C9直链/支链烷基、C10直链/支链烷基。
本发明所述的术语C3-10支链烷基,包括异丙基、异丁基、叔丁基、异戊基。
本发明所述的术语C3-10环烃基,包括C3环烃基、C4环烃基、C5环烃基、C6环烃基、 C7环烃基、C8环烃基、C9环烃基、C10环烃基。
本发明所述的术语卤素,包括氟、氯、溴、碘。
本发明所述的术语杂环烃基包括脂肪族杂环基、芳香族杂环基,优选1至3个单环和 /或稠环及3至约18个环原子的芳香族杂环基和脂肪族杂环基。
本发明所述的术语杂环烷基是指含3-10个环原子,优选5-10个环原子的非芳香的饱和单环或多环环系,其中的一个或多个环原子不是碳原子,而是例如氮、氧或硫原子。优选的杂环烷基含有5-6个环原子。杂环烷基前的前缀氮杂、氧杂或硫杂分别是指至少有一个氮、氧或硫原子作为环原子。
本发明所述的术语杂环芳香基是指含5-14个环原子,优选5-10个环原子的芳香单环或多环环系,其中的一个或多个环原子不是碳原子,而是例如氮、氧或硫原子。优选的杂环芳香基含有5-6个环原子。代表性的杂环芳香基包括吡嗪基、呋喃基、噻吩基、吡啶基、嘧啶基、异噁唑基、异噻唑基、噁唑基、噻唑基、吡唑基、吡咯基、吡唑基、***基、吡嗪基、哒嗪基、喹喔啉基、2,3-二氮杂萘基、咪唑并[1,2-a]吡啶、咪唑并[2,1-b]噻唑基、吲哚基、氮杂吲哚基、苯并咪唑基、苯并噻吩基、喹啉基、咪唑基、噻吩并吡啶基、喹唑啉基、噻吩并嘧啶基、吡咯并吡啶基、咪唑并吡啶基、异喹啉基、1,2,4-三嗪基、苯并噻唑基等。
附图说明
图1所示为C1、C2、C3化合物处理时的HPK1表达图。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅是本发明的部分实施例,而不是全部。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1化合物C1的制备
于250ml圆底烧瓶中,加入3-羟基苯二甲酸酐(2g,12.2mmol,1.0equiv)与3-氨基-2,6-哌啶二酮盐酸盐(2g,12.2mmol,1.0equiv)和适量甲苯,待充分混合后向反应体系中加入三乙胺(1860ul,13.4mmol,1.1equiv)。加热回流12h后,停止加热。待反应体系恢复至室温,于旋转蒸发仪上除去甲苯。粗产物通过硅胶柱层析进行纯化(V甲醇:V二氯甲烷=1:40),得终产物2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮1.9032g,淡黄色固体,产率为57%。
NMR:1H NMR(400MHz,DMSO)δ11.15(s,1H),11.07(s,1H),7.62(t,J=7.7Hz,1H),7.29(d,J=7.1Hz,1H),7.22(d,J=8.4Hz,1H),5.05(dd,J=12.8,5.1Hz,1H),3.04–2.73(m, 1H),2.68–2.34(m,1H),2.17–1.73(m,1H).13C NMR(100MHz,DMSO)δ173.28,170.49,167.50,166.30,155.94,136.86,133.63,124.03,114.84,114.77,49.11,31.60,22.80.
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(100mg,0.4mmol,1.0equiv),碘化钾(6.1mg,0.03mmol,0.1equiv)和碳酸氢钠(61.3mg,0.4mmol,2.0equiv)溶于DMF中,向反应体系中加入8-溴-1-辛醇(100.4mg,0.48mmo,1.2equiv),之后将反应体系加热至80℃,反应过夜。中止加热,待反应体系降至室温,加入适量乙酸乙酯稀释,并用饱和食盐水萃取5次,取有机相加入无水硫酸钠干燥,过滤,旋干,粗产物通过硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2),得终产物103.6mg,产率64%,LC-MS:m/z=403。
将2-1(92.6mg,0.23mmol,1.0equiv),沙瑞特试剂PCC(99.2mg,0.46mmol,2.0equiv)溶于适量二氯甲烷中,室温搅拌6h,向反应体系中加入适量硅胶,旋干,硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2),得终产物2-291mg,产率99%,LC-MS:m/z=401。
将2-2(54.3mg,0.14mmol,1.0equiv),过硫酸氢钾复合盐(oxone)(83.4mg,0.14mol,1.0 equiv)溶于适量DMF中,室温搅拌过夜,向反应体系加入乙酸乙酯稀释并用水和饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,过滤,旋干,得终产物2-347.9mg,产率82%, LC-MS:m/z=417。
将2-3(10mg,0.024mmol,1.1equiv)溶于适量DMF中,0℃搅拌,加入苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸酯(HBTU)(18.3mg,0.048mmol,2.0equiv),5分钟后,依次加入DIEA(9.3mg,0.072mmol,3.0equiv)和化合物1(10mg,0.022mmol,1.0equiv),(化合物1 的制备方法可参考专利CN201810945948.2以及CN201810946081.2)升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物2-417mg,产率91.3%,LC-MS:m/z=847。
NMR:1H NMR(400MHz,DMSO)δ11.13(s,1H),7.89(s,1H),7.85–7.72(m,2H),7.63 –7.46(m,3H),7.41(dd,J=16.7,7.8Hz,2H),7.34(m,J=7.5Hz,2H),6.10(s,2H),5.48(s,1H),5.22(s,2H),5.09(dd,J=12.8,5.2Hz,1H),4.43(d,J=12.7Hz,1H),4.19(s,2H),3.93(d, J=13.0Hz,1H),3.20(dt,J=24.9,11.5Hz,2H),3.01–2.80(m,1H),2.72(t,J=12.1Hz,1H), 2.66–2.43(m,2H),2.33(t,J=7.1Hz,2H),2.04(dd,J=21.1,13.0Hz,3H),1.85–1.70(m, 2H),1.69–1.58(m,1H),1.58–1.49(m,4H),1.47(s,6H),1.32(m,4H),1.24–1.11(m,1H). 13C NMR(101MHz,DMSO)δ173.24,171.83,170.95,170.42,167.31,165.77,156.47,151.49, 140.68,137.66,137.46,137.09,136.93,135.88,133.70,131.14,130.71,129.25,128.00,123.19, 120.21,116.67,116.33,115.56,115.06,96.78,80.67,69.25,69.19,64.07,49.20,45.10,41.14, 33.07,32.77,32.40,32.06,31.44,29.21,28.99,28.86,25.70,25.30,22.48.13CNMR(101MHz, DMSO)δ173.24,171.83,170.95,170.42,167.31,165.77,156.47,151.49,140.68,137.66, 137.46,137.09,136.93,135.88,133.70,131.14,130.71,129.25,128.00,123.19,120.21,116.67, 116.33,115.56,115.06,96.78,80.67,69.25,69.19,64.07,49.20,45.10,41.14,33.07,32.77,32.40,32.06,31.44,29.21,28.99,28.86,25.70,25.30,22.48,21.78,14.55。
实施例2化合物C2的制备
将C1(12mg,0.014mmol,1.0equiv)溶于适量DMF中,依次加入碳酸钾(3.9mg,0.021mmol,1.5equiv)和碘甲烷(2.4mg,0.017mmol,1.2equiv),室温搅拌过夜,待反应完全,加入适量乙酸乙酯稀释,饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,硅胶柱层析纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物 2-58.2mg,产率68%,LC-MS:m/z=861。
NMR:1H NMR(400MHz,DMSO)δ7.88(s,1H),7.84–7.77(m,1H),7.76(d,J=1.5Hz,1H),7.56–7.48(m,3H),7.45–7.36(m,2H),7.36–7.30(m,2H),6.09(s,2H),5.46(s,1H),5.21(s,2H),5.15(dd,J=13.0,5.4Hz,1H),4.42(d,J=12.9Hz,1H),4.20(t,J=6.3Hz,2H), 3.93(d,J=13.5Hz,1H),3.29–3.09(m,3H),2.98(s,3H),2.96–2.87(m,1H),2.81–2.65(m, 2H),2.62–2.51(m,2H),2.33(t,J=7.3Hz,2H),2.12–1.97(m,3H),1.83–1.69(m,2H),1.69 –1.56(m,1H),1.57–1.47(m,3H),1.45(s,6H),1.44–1.40(m,1H),1.30–1.15(m,3H).13C NMR(101MHz,DMSO)δ172.24,171.87,170.97,170.17,167.30,165.78,156.53,151.50, 140.70,137.68,137.52,137.08,136.96,135.89,133.71,131.15,130.73,129.27,128.02,123.20, 120.28,116.68,116.34,115.60,115.13,96.80,80.68,69.29,69.21,64.08,49.78,45.11,41.14, 33.08,33.07,32.77,32.40,32.07,31.58,29.20,28.98,28.86,27.07,25.71,25.30,21.68。
实施例3化合物C3的制备
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(300mg,1.1mmol,1.0equiv),碘化钾(18.2mg,0.1mmol,0.1equiv)和碳酸氢钠(183.8mg,2.2mmol,2.0equiv)溶于DMF中,向反应体系中加入10-溴-1-癸醇(314mg,1.32mmol,1.2equiv)。之后将反应体系加热至80℃,反应过夜,中止加热,待反应体系降至室温,加入适量乙酸乙酯稀释,并用饱和食盐水萃取5 次,取有机相加入无水硫酸钠干燥,过滤,旋干。粗产物通过硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2),得终产物253.3mg,产率53%,LC-MS:m/z=431。
将3-1(190mg,0.32mmol,1.0equiv),PCC(190mg,0.64mmol,2.0equiv)溶于适量二氯甲烷中,室温搅拌6h,向反应体系中加入适量硅胶,旋干,硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2),得终产物3-2135.5mg,产率99%,LC-MS:m/z=429。
将3-2(135.5mg,0.32mmol,1.0equiv),oxone(197mg,0.32mmol,1.0equiv)溶于适量 DMF中,室温搅拌过夜,向反应体系加入乙酸乙酯稀释并用水和饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,过滤,旋干,得终产物3-3112.6mg,产率79%,LC-MS: m/z=445。
将3-3(12.2mg,0.028mmol,1.1equiv)溶于适量DMF中,0℃搅拌,加入HBTU(19mg,0.05mmol,2.0equiv),5分钟后,依次加入DIEA(9.7mg,0.075mmol,3.0equiv)和化合物 1(11mg,0.025mmol,1.0equiv),升温至室温,搅拌过夜,向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物3-415.7mg,产率72%,LC-MS:m/z=875。
NMR:1H NMR(400MHz,DMSO)δ11.13(s,1H),7.89(s,1H),7.84–7.77(m,1H),7.76(s,1H),7.53(s,2H),7.47(dd,J=25.3,7.9Hz,2H),7.42–7.36(m,1H),7.34(d,J=7.4Hz,2H),6.11(s,2H),5.49(s,1H),5.22(s,2H),5.09(dd,J=12.9,5.2Hz,1H),4.43(d,J=12.2Hz, 1H),4.19(t,J=6.2Hz,2H),3.93(d,J=13.5Hz,1H),3.30–3.11(m,4H),2.99–2.78(m,2H), 2.78–2.65(m,1H),2.64–2.53(m,2H),2.35–2.25(m,2H),2.14–1.92(m,4H),1.83–1.48 (m,6H),1.47(s,6H),1.43–1.32(m,3H),1.24–1.15(m,4H).13C NMR(101MHz,DMSO)δ 173.28,171.84,170.96,170.44,167.32,165.77,156.47,151.49,140.65,137.67,137.49,137.08, 136.93,135.89,133.69,131.13,130.71,129.26,128.10,128.02,123.16,120.21,116.65,116.29, 115.58,115.06,115.03,96.77,80.66,69.22,69.14,64.06,49.18,45.11,41.13,33.08,32.80, 32.42,32.05,31.42,29.37,29.27,29.24,29.09,28.87,25.73,25.37,22.46。
实施例4化合物C4的制备
将C3(15.7mg,0.018mmol,1.0equiv)溶于适量DMF中,依次加入碳酸钾(3.7mg,0.027mmol,1.5equiv)和碘甲烷(3.1mg,0.022mmol,1.2equiv),室温搅拌过夜,待反应完全,加入适量乙酸乙酯稀释,饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,硅胶柱层析纯化(V(甲醇):V(二氯甲烷)=1:20)得终产物10.4mg,产率65%,LC-MS:m/z=889。
实施例5化合物C5的制备
向二缩三乙二醇(5.9g,39mmol,5.0equiv)的乙腈溶液中加入丙烯酸叔丁酯(1g,7.8mmol, 1.0equiv)和苄基三甲基氢氧化铵(TritonB)(121mg,0.29mmol,1.0equiv,40%水溶液),室温搅拌48h,KMnO4显色确定反应是否完全,于旋转蒸发仪上除去溶剂,通过硅胶柱层析(V(石油醚):V(乙酸乙酯)=2:1),纯化得目标产物4-11.6632g,油状液体,产率77%。
在氩气保护下将三苯基膦(1007.2mg,3.84mmol,1.2equiv),咪唑(261.4mg,3.84mmol,1.2 equiv)和碘(1218.3mg,4.8mmol,1.5equiv)溶于四氢呋喃(超干),待充分混合,将 4-1(900mg,3.2mmol,1.0equiv)逐滴加入反应体系。室温搅拌3h,TLC监测反应,KMnO4显色。待反应完全,过滤除去白色沉淀,之后于旋转蒸发仪上浓缩,并通过硅胶柱层析(V(石油醚):V(乙酸乙酯)=1:2),纯化得终产物4-21208.8mg,棕色油状液体,产率97%。
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(181mg,0.66mmol,1.0equiv)和碳酸铯(644mg,1.98mmol,3.0equiv)溶于DMF中,向反应体系中逐滴加入4-2(307.5mg,0.79mmol,1.2 equiv),加热反应体系至50℃,搅拌过夜,待反应完全后,加入适量乙酸乙酯稀释,并依次用水和饱和碳酸氢钠溶液的混合液(V(水):V(饱和碳酸氢钠溶液)=1:5),饱和食盐水萃取,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,硅胶柱层析纯化(V(丙酮): V(石油醚)=1:2),得终产物4-3194mg,产率55%,LC-MS:m/z=535。
将4-3(40mg,0.075mmol,1.0equiv)溶于适量二氯甲烷中,在0℃下加入2倍体积的三氟乙酸,继续搅拌2h,LC-MS监测反应完全,在旋转蒸发仪上除去二氯甲烷和三氟乙酸,并在真空泵下干燥2h以除去残留的溶剂和酸,粗产物4-4(35.4mg)可不需要进一步纯化直接用于下一步,LC-MS:m/z=479。
将4-4(23.7mg,0.05mmol,1.1equiv)溶于适量DMF中,0℃搅拌,加入HBTU (34mg,0.09mmol,2.0equiv),5分钟后,依次加入DIEA(17.2mg,0.13mmol,3.0equiv)和化合物1(20mg,0.045mmol,1.0equiv),升温至室温,搅拌过夜,向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物20.1mg,产率 51%,LC-MS:m/z=909。
NMR:1H NMR(400MHz,DMSO)δ7.89(s,1H),7.77(s,1H),7.71–7.61(m,1H),7.53(s,2H),7.39(m,3H),7.29(dd,J=25.0,7.8Hz,2H),6.10(s,2H),5.48(s,1H),5.22(s,2H),5.16(dd,J=13.0,5.3Hz,1H),4.42(d,J=13.2Hz,1H),3.97(d,J=13.1Hz,1H),3.83(m,2H), 3.64(t,J=6.6Hz,2H),3.50(d,J=6.0Hz,6H),3.43(t,J=6.6Hz,2H),3.27–3.08(m,2H), 3.07–2.85(m,2H),2.72(dd,J=24.3,12.1Hz,2H),2.60(m,2H),2.13–1.92(m,4H),1.76– 1.53(m,2H),1.47(s,6H).13C NMR(101MHz,DMSO)δ171.98,171.85,170.00,169.10,167.44,165.41,156.04,151.49,148.07,140.68,137.89,137.67,137.10,136.93,136.85,135.88, 133.59,132.78,131.13,130.71,130.11,129.25,128.01,124.09,123.18,121.86,118.15,117.33, 116.33,115.08,114.79,114.72,96.78,95.65,88.52,80.67,70.24,70.14,70.07,69.18,67.36, 67.18,64.07,49.71,33.28,32.06,31.59,29.55,29.49,29.44,22.56,21.73.
实施例6化合物C6的制备
将C5(10mg,0.011mmol,1.0equiv)溶于DMF并依次加入碳酸钾(2.3mg,0.017mmol,1.5 equiv)和碘甲烷((2mg,0.013mmol,1.2equiv),室温搅拌过夜,待反应完全,加入适量乙酸乙酯稀释,饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,硅胶柱层析纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物10.2mg,产率81%,LC-MS: m/z=923。
NMR:1H NMR(400MHz,CDCl3)δ7.83(s,1H),7.72–7.65(m,1H),7.64(s,1H),7.50(s,1H),7.45(d,J=7.3Hz,1H),7.42–7.30(m,3H),7.22(d,J=8.5Hz,1H),7.06(d,J=1.4Hz,1H),5.34(t,J=4.7Hz,1H),5.08(s,2H),4.97(dd,J=12.1,5.7Hz,1H),4.92(s,2H),4.65(d,J =13.3Hz,1H),4.08–3.97(m,5H),3.79(t,J=6.8Hz,2H),3.66–3.55(m,9H),3.25–3.13 (m,2H),3.01–2.87(m,1H),2.83–2.71(m,3H),2.71–2.64(m,2H),2.24–1.99(m,5H),1.82–1.70(m,2H),1.62(s,6H).13C NMR(101MHz,CDCl3)δ172.58,171.10,169.57,168.71,167.23,166.12,157.09,150.22,141.28,137.24,136.88,136.73,136.10,135.78,133.97,131.83, 131.08,130.05,128.93,127.62,123.51,118.09,117.92,117.20,115.98,115.24,94.83,81.61, 70.62,70.12,67.64,67.58,65.63,56.51,45.61,41.50,40.76,39.42,36.06,33.78,32.87,32.11, 31.61,29.46,27.35,25.67,22.83,22.12.
实施例7化合物C7的制备
向三缩四乙二醇(5.9g,39mmol,5.0equiv)的乙腈溶液中加入丙烯酸叔丁酯(1g,7.8mmol, 1.0equiv)和TritonB(121mg,0.29mmol,1.0equiv,40%水溶液),室温搅拌48h,KMnO4显色确定反应是否完全,于旋转蒸发仪上除去溶剂,通过硅胶柱层析(V(石油醚):V(乙酸乙酯)=2:1)纯化得目标产物1.8954g,油状液体,产率75%。
在氩气保护下将三苯基膦(879.7mg,3.4mmol,1.2equiv),咪唑(228.3mg,3.4mmol,1.2 equiv)和碘(1064mg,4.2mmol,1.5equiv)溶于四氢呋喃(超干),待充分混合,将4-1(900mg, 2.8mmol,1.0equiv)逐滴加入反应体,室温搅拌3h,TLC监测反应,KMnO4显色,待反应完全,过滤除去白色沉淀,之后于旋转蒸发仪上浓缩,并通过硅胶柱层析(V(石油醚): V(乙酸乙酯)=1:2)纯化得终产物1150.6mg,棕色油状液体,产率95%。
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(470.7mg,1.7mmol,1.0equiv)和碳酸铯(1678mg,5.2mmol,3.0equiv)溶于DMF中,向反应体系中逐滴加入5-2(307.5mg,0.79mmol,1.2 equiv),加热反应体系至50℃,搅拌过夜,待反应完全后,加入适量乙酸乙酯稀释,并依次用水和饱和碳酸氢钠溶液的混合液(V(水):V(饱和碳酸氢钠溶液)=1:5),饱和食盐水萃取,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,硅胶柱层析纯化(V(丙酮): V(石油醚)=1:2),得终产物463.1mg,产率47%,LC-MS:m/z=579。
将5-3(40mg,0.084mmol,1.0equiv)溶于适量二氯甲烷中,在0℃下加入2倍体积的三氟乙酸,继续搅拌2h,LC-MS监测反应完,在旋转蒸发仪上除去二氯甲烷和三氟乙酸,并在真空泵下干燥2h以除去残留的溶剂和酸,粗产物5-4(43.6mg)可不需要进一步纯化直接用于下一步,LC-MS:m/z=523。
将5-4(26mg,0.05mmol,1.1equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(34mg,0.09mmol,2.0equiv),5分钟后,依次加入DIEA(17.2mg,0.13mmol,3.0equiv)和化合物1(20mg,0.045mmol,1.0equiv),升温至室温,搅拌过夜,向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物5-522.6mg,产率44%,LC-MS:m/z=953。
NMR:1H NMR(400MHz,DMSO)δ7.91(d,J=12.6Hz,1H),7.77(d,J=1.7Hz,1H),7.70–7.60(m,1H),7.54(m,2H),7.47–7.32(m,3H),7.27(dd,J=22.9,7.8Hz,2H),6.10(s,2H),5.22(s,2H),5.16(dd,J=13.0,5.4Hz,1H),4.42(d,J=12.8Hz,1H),3.97(d,J=13.4Hz, 1H),3.84(m,2H),3.63(t,J=6.7Hz,2H),3.46–3.12(m,12H),3.06–2.89(m,1H),2.86– 2.66(m,2H),2.66–2.52(m,2H),2.02(dd,J=19.6,16.5Hz,3H),1.75–1.51(m,2H),1.47(s, 6H).13C NMR(101MHz,DMSO)δ172.03,171.93,170.02,169.20,167.50,166.38,156.38, 151.47,140.70,137.65,137.07,136.94,136.85,135.87,133.58,131.17,130.70,129.28,128.02, 124.27,123.18,116.38,115.09,114.73,114.56,99.99,96.76,80.69,70.24,70.22,70.14,70.12, 70.06,69.20,67.34,67.19,64.10,49.70,45.21,41.15,39.11,33.28,32.97,32.27,32.04,31.60, 21.73.
实施例8化合物8的制备
向5-溴-1-戊醇(260mg,0.78mmol,1.0equiv)的乙腈溶液中加入丙烯酸叔丁酯(200mg,1.56mmol,2.0equiv)和TritonB(10mg,0.09mmol,1.0equiv,40%水溶液),室温搅拌 48h,KMnO4显色确定反应是否完全,于旋转蒸发仪上除去溶剂,通过硅胶柱层析(V(石油醚):V(乙酸乙酯)=50:1)纯化得目标产物178mg,油状液体,产率77%。
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(150mg,0.55mmol,1.0equiv),碘化钾(9mg,0.054mmol,0.1equiv)和碳酸氢钠(92mg,1.1mmol,2.0equiv)溶于DMF中,向反应体系中加入6-1(162mg,0.55mmol,1.2equiv),之后将反应体系加热至80℃,反应过夜,中止加热,待反应体系降至室温,加入适量乙酸乙酯稀释,并用饱和食盐水萃取5次,取有机相加入无水硫酸钠干燥,过滤,旋干,粗产物通过硅胶柱层析进行纯化(V(石油醚):V(丙酮)=3: 1),得终产物6-2164.7mg,产率61%,LC-MS:m/z=489。
将6-2(164.7mg,0.34mmol,1.0equiv)溶于适量二氯甲烷中,在0℃下加入2倍体积的三氟乙酸,继续搅拌2h,LC-MS监测反应完全,在旋转蒸发仪上除去二氯甲烷和三氟乙酸,并在真空泵下干燥2h以除去残留的溶剂和酸,粗产物6-3(145mg)可不需要进一步纯化直接用于下一步,LC-MS:m/z=433。
将6-3(21.6mmg,0.05mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入HBTU(34mg,0.09mmol,2.0equiv),5分钟后,依次加入DIEA(17.2mg,0.13mmol,3.0equiv)和化合物1(20mg,0.045mmol,1.0equiv),升温至室温,搅拌过夜,向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物10.5mg,产率27%,LC-MS:m/z=863。
NMR:1H NMR(400MHz,CDCl3)δ7.82(s,1H),7.71–7.59(m,2H),7.51(s,1H),7.46–7.38(m,2H),7.35(d,J=5.7Hz,2H),7.18(d,J=8.4Hz,1H),7.07(s,1H),5.42–5.32(m,1H), 5.09(s,2H),4.93(d,J=9.7Hz,1H),4.68(t,J=5.7Hz,2H),4.38–3.96(m,4H),3.75(t,J= 6.6Hz,2H),3.48(d,J=8.1Hz,3H),3.34–3.07(m,2H),3.02–2.48(m,7H),2.43–2.07(m, 6H),2.07–1.95(m,3H),1.62(s,6H).
实施例9化合物C9的制备
向6-溴-1-己醇(260mg,0.78mmol,1.0equiv)的乙腈溶液中加入丙烯酸叔丁酯(200mg,1.56mmol,2.0equiv)和TritonB(10mg,0.09mmol,1.0equiv,40%水溶液),室温搅拌 48h,KMnO4显色确定反应是否完全,于旋转蒸发仪上除去溶剂,通过硅胶柱层析(V(石油醚):V(乙酸乙酯)=50:1)纯化得目标产物7-1174.4mg,油状液体,产率72%。
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(150mg,0.55mmol,1.0equiv),碘化钾(9mg,0.054mmol,0.1equiv)和碳酸氢钠(92mg,1.1mmol,2.0equiv)溶于DMF中,向反应体系中加入7-1(169mg,0.55mmol,1.2equiv),之后将反应体系加热至80℃,反应过夜,中止加热,待反应体系降至室温,加入适量乙酸乙酯稀释,并用饱和食盐水萃取5次,取有机相加入无水硫酸钠干燥,过滤,旋干,粗产物通过硅胶柱层析进行纯化(V(石油醚):V(丙酮)=3: 1),得终产物7-2163mg,产率59%,LC-MS:m/z=503。
将7-2(163mg,0.32mmol,1.0equiv)溶于适量二氯甲烷中,在0℃下加入2倍体积的三氟乙酸,继续搅拌2h,LC-MS监测反应完全。在旋转蒸发仪上除去二氯甲烷和三氟乙酸,并在真空泵下干燥2h以除去残留的溶剂和酸,粗产物7-3(144.5mg)可不需要进一步纯化直接用于下一步,LC-MS:m/z=447。
将7-3(22.3mmg,0.05mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(34mg,0.09mmol,2.0equiv),5分钟后,依次加入DIEA(17.2mg,0.13mmol,3.0equiv)和化合物1(20mg,0.045mmol,1.0equiv),升温至室温,搅拌过夜,向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物26mg,产率65%,LC-MS:m/z=877。
NMR:1H NMR(400MHz,CDCl3)δ7.76(d,J=1.2Hz,1H),7.69–7.58(m,2H),7.46(s,1H),7.43–7.35(m,2H),7.35–7.28(m,2H),7.16(dd,J=8.5,3.7Hz,1H),7.04(d,J=1.4Hz,1H),5.52(s,1H),5.03(s,2H),4.98–4.84(m,1H),4.65(d,J=13.4Hz,1H),4.12(d,J=2.3Hz,3H),3.99(d,J=13.7Hz,1H),3.84–3.62(m,2H),3.54–3.37(m,4H),3.18(dd,J=27.3,12.0Hz,2H),2.98–2.52(m,7H),2.11(dd,J=20.1,10.2Hz,3H),1.93–1.65(m,3H),1.61(s,6H),1.54–1.29(m,5H).13C NMR(101MHz,CDCl3)δ172.64,171.94,169.76,168.68,167.16,165.69,156.59,150.37,141.22,136.72,136.44,135.89,135.64,135.41,133.79,131.67,130.90, 128.78,127.46,123.41,118.90,117.38,117.08,115.65,115.06,94.87,81.41,71.09,70.02, 69.25,67.14,66.23,65.40,49.12,45.63,41.50,40.56,35.32,33.70,32.81,32.12,31.47,29.47, 28.78,25.76,25.59,22.66.
实施例10化合物C10的制备
向7-溴-1-庚醇(260mg,0.78mmol,1.0equiv)的乙腈溶液中加入丙烯酸叔丁酯(200mg,1.56mmol,2.0equiv)和TritonB(10mg,0.09mmol,1.0equiv,40%水溶液),室温搅拌 48h,KMnO4显色确定反应是否完全,于旋转蒸发仪上除去溶剂,通过硅胶柱层析(V(石油醚):V(乙酸乙酯)=50:1),纯化得目标产物8-1258.6mg,油状液体,产率80%。
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(150mg,0.55mmol,1.0equiv),碘化钾(9mg,0.054mmol,0.1equiv)和碳酸氢钠(92mg,1.1mmol,2.0equiv)溶于DMF中,向反应体系中加入8-1(177mg,0.55mmol,1.0equiv),之后将反应体系加热至80℃,反应过夜,中止加热,待反应体系降至室温,加入适量乙酸乙酯稀释,并用饱和食盐水萃取5次,取有机相加入无水硫酸钠干燥,过滤,旋干,粗产物通过硅胶柱层析进行纯化(V(石油醚):V(丙酮)=3: 1),得终产物8-2179mg,产率63%,LC-MS:m/z=517。
将8-2(179mg,0.35mmol,1.0equiv)溶于适量二氯甲烷中,在0℃下加入2倍体积的三氟乙酸,继续搅拌2h,LC-MS监测反应完全。在旋转蒸发仪上除去二氯甲烷和三氟乙酸,并在真空泵下干燥2h以除去残留的溶剂和酸,粗产物8-3(158.3mg)可不需要进一步纯化直接用于下一步,LC-MS:m/z=461。
将8-3(23mmg,0.05mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(34mg,0.09mmol,2.0equiv),5分钟后,依次加入DIEA(17.2mg,0.13mmol,3.0equiv)和化合物1(20mg,0.045mmol,1.0equiv),升温至室温,搅拌过夜,向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干。粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物28mg,,产率70%,LC-MS:m/z=891。
NMR:1H NMR(400MHz,CDCl3)δ7.75(s,1H),7.70–7.55(m,2H),7.47(s,1H),7.44–7.35(m,2H),7.36–7.28(m,2H),7.16(dd,J=8.4,5.1Hz,1H),7.05(d,J=1.5Hz,1H),5.68(s,2H),5.04(s,2H),4.97–4.87(m,2H),4.66(d,J=13.2Hz,1H),4.28–4.05(m,3H),4.00(d, J=12.9Hz,1H),3.82–3.62(m,3H),3.54–3.35(m,4H),3.31–3.08(m,2H),2.91–2.45(m, 9H),2.32–1.95(m,4H),1.90–1.63(m,5H),1.61(s,6H).13C NMR(101MHz,CDCl3)δ172.76,171.96,169.74,168.64,167.15,165.69,156.61,150.36,141.31,136.77,136.44,135.80, 135.29,133.79,131.70,130.91,128.79,127.46,123.43,118.85,117.27,117.05,115.64,115.11, 94.89,81.39,71.20,70.08,69.36,67.11,66.15,65.41,49.10,45.64,41.48,40.58,35.27,33.73, 32.78,32.14,31.46,29.53,29.37,29.04,28.78,26.03,25.78,22.64.
实施例11化合物C11的制备
向8-溴-1-辛醇(260mg,0.78mmol,1.0equiv)的乙腈溶液中加入丙烯酸叔丁酯(200mg,1.56mmol,2.0equiv)和TritonB(10mg,0.09mmol,1.0equiv,40%水溶液),室温搅拌 48h,KMnO4显色确定反应是否完全,于旋转蒸发仪上除去溶剂,通过硅胶柱层析(V(石油醚):V(乙酸乙酯)=50:1)纯化得目标产物9-1198.4mg,油状液体,产率75%。
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(150mg,0.55mmol,1.0equiv),碘化钾(9mg,0.054mmol,0.1equiv)和碳酸氢钠(92mg,1.1mmol,2.0equiv)溶于DMF中,向反应体系中加入9-1(184mg,0.55mol,1.0equiv),之后将反应体系加热至80℃,反应过夜,中止加热,待反应体系降至室温,加入适量乙酸乙酯稀释,并用饱和食盐水萃取5次,取有机相加入无水硫酸钠干燥,过滤,旋干,粗产物通过硅胶柱层析进行纯化(V(石油醚):V(丙酮)=3: 1),得终产物9-2160.5mg,产率55%,LC-MS:m/z=531。
将9-2(160.5mg,0.30mmol,1.0equiv)溶于适量二氯甲烷中,在0℃下加入2倍体积的三氟乙酸,继续搅拌2h,LC-MS监测反应完全,在旋转蒸发仪上除去二氯甲烷和三氟乙酸,并在真空泵下干燥2h以除去残留的溶剂和酸,粗产物9-3(143mg)可不需要进一步纯化直接用于下一步,LC-MS:m/z=475。
将9-3(23.7mmg,0.05mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(34mg,0.09mmol,2.0equiv),5分钟后,依次加入DIEA(17.2mg,0.13mmol,3.0equiv)和化合物1(20mg,0.045mmol,1.0equiv),升温至室温,搅拌过夜,向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物21.6mg,产率53%,LC-MS:m/z=905。
NMR:1H NMR(400MHz,CDCl3)δ10.12(s,1H),7.85(d,J=1.2Hz,1H),7.78–7.59(m,2H),7.50(s,1H),7.46–7.39(m,2H),7.38–7.30(m,2H),7.20(d,J=8.5Hz,1H),7.07(d,J=1.4Hz,1H),5.25(s,1H),5.07(s,2H),4.95(dd,J=12.0,5.2Hz,1H),4.68(d,J=13.4Hz,1H), 4.15(t,J=6.4Hz,2H),4.02(d,J=13.5Hz,1H),3.75(dd,J=10.9,6.6Hz,2H),3.45(t,J=6.6 Hz,2H),3.21(dd,J=23.6,11.8Hz,2H),3.05–2.40(m,8H),2.33–2.00(m,4H),2.00–1.68 (m,4H),1.64(s,6H),1.60–1.40(m,5H),1.33(s,4H).13C NMR(101MHz,CDCl3)δ172.50, 171.98,171.93,169.67,167.16,165.70,156.67,150.28,141.12,136.74,136.60,136.41,136.08, 135.97,135.58,133.82,131.66,130.89,128.76,127.43,123.43,118.92,117.62,117.12,117.10, 115.64,115.07,94.86,81.42,71.30,70.01,69.39,67.10,65.34,49.12,45.60,41.46,40.61, 33.76,32.80,32.09,31.46,29.60,29.23,29.12,28.83,26.02,25.68,22.66.
实施例12化合物C12的制备
向9-溴-1-壬醇(260mg,0.78mmol,1.0equiv)的乙腈溶液中加入丙烯酸叔丁酯(200mg,1.56mmol,2.0equiv)和TritonB(10mg,0.09mmol,1.0equiv,40%水溶液),室温搅拌 48h,KMnO4显色确定反应是否完全,于旋转蒸发仪上除去溶剂,通过硅胶柱层析(V(石油醚):V(乙酸乙酯)=50:1),纯化得目标产物10-1274mg,油状液体,产率73%。
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(150mg,0.55mmol,1.0equiv),碘化钾(9mg,0.054mmol,0.1equiv)和碳酸氢钠(92mg,1.1mmol,2.0equiv)溶于DMF中,向反应体系中加入10-1(192mg,0.55mmol,1.0equiv),之后将反应体系加热至80℃,反应过夜,中止加热,待反应体系降至室温,加入适量乙酸乙酯稀释,并用饱和食盐水萃取5次,取有机相加入无水硫酸钠干燥,过滤,旋干,粗产物通过硅胶柱层析进行纯化(V(石油醚):V(丙酮)=3: 1),得终产物10-2176.7mg,产率59%,LC-MS:m/z=545。
将10-2(176.7mg,0.32mmol,1.0equiv)溶于适量二氯甲烷中,在0℃下加入2倍体积的三氟乙酸,继续搅拌2h,LC-MS监测反应完全,在旋转蒸发仪上除去二氯甲烷和三氟乙酸,并在真空泵下干燥2h以除去残留的溶剂和酸,粗产物10-3(158.5mg)可不需要进一步纯化直接用于下一步,LC-MS:m/z=489。
将10-3(24.2mmg,0.05mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入HBTU(34mg,0.09mmol,2.0equiv),5分钟后,依次加入DIEA(17.2mg,0.13mmol,3.0equiv)和化合物 1(20mg,0.045mmol,1.0equiv),升温至室温,搅拌过夜,向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物10-427.7mg,,产率67%,LC-MS:m/z=919。
NMR:1H NMR(400MHz,CDCl3)δ7.77(s,1H),7.70–7.58(m,2H),7.48(s,1H),7.45–7.36(m,2H),7.36–7.30(m,1H),7.19(d,J=8.4Hz,2H),7.07(s,1H),5.72(s,2H),5.06(d,J=3.6Hz,2H),5.01–4.87(m,2H),4.66(d,J=12.7Hz,1H),4.12(dd,J=12.1,5.1Hz,4H),4.01(d,J=12.1Hz,1H),3.73(m,3H),3.45(dd,J=12.5,6.3Hz,3H),3.34–3.07(m,2H),2.76(m,11H),2.27–1.96(m,5H),1.91–1.66(m,5H),1.62(s,6H).13C NMR(101MHz, CDCl3)δ172.69,171.92,169.72,168.68,167.15,165.69,156.66,150.46,141.31,136.77,136.43,135.83,135.31,133.78,131.67,130.86,128.77,127.40,123.44,118.93,118.89,117.21, 117.06,115.62,115.16,94.95,81.36,71.30,71.19,70.07,69.43,69.39,67.07,66.11,65.38, 65.35,49.10,45.59,41.45,40.53,36.54,35.21,33.73,32.75,32.08,31.46,29.61,29.49,29.36, 29.29,29.24,29.12,28.84,26.07,26.00,25.73,25.71,22.63.
实施例13化合物C13的制备
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(100mg,0.4mmol,1.0equiv),碘化钾(6.1mg,0.03mmol,0.1equiv)和碳酸氢钠(61.3mg,0.4mmol,2.0equiv)溶于DMF中,向反应体系中加入2-(4-溴丁氧基)四氢-2H-吡喃(113.8mg,0.48mmol,1.2equiv)。之后将反应体系加热至80℃,反应过夜。终止加热,待反应体系降至室温,加入适量乙酸乙酯稀释,并用饱和食盐水萃取5次,取有机相加入无水硫酸钠干燥,过滤,旋干。粗产物通过硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2),得终产物113.6mg,产率66%,LC-MS:m/z=431.2。
称取11-1(113.6mg,0.26mmol)至圆底烧瓶,加入4M的盐酸二氧六环溶液,室温搅拌至反应完全。旋转蒸发除去多余溶剂,得终产物84mg,产率93%,LC-MS:m/z=347.1。
将11-2(84mg,0.24mmol,1.0equiv),PCC(103.5mg,0.48mmol,2.0equiv)溶于适量二氯甲烷中,室温搅拌6h。向反应体系中加入适量硅胶,旋干,硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2),得终产物81mg,产率98%,LC-MS:m/z=345.1。
将11-3(81mg,0.24mmol,1.0equiv),oxone(140.1mg,0.24mol,1.0equiv)溶于适量DMF中,室温搅拌过夜。向反应体系加入乙酸乙酯稀释并用水和饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,过滤,旋干,得终产物70.9mg,产率82%,LC-MS:m/z=361.1。
将11-4(50mg,0.14mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(105.8mg,0.28mmol,2.0equiv),5分钟后,依次加入DIEA(71.5mg,0.56mmol,4.0equiv)和Β-丙氨酸叔丁酯盐酸盐(25.4mg,0.14mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干。粗产物通过硅胶柱层析进行纯化,得终产物44.4mg,产率65%,LC-MS:m/z=488.2。
将11-5(44.4mg,0.09mmol)溶于适量二氯甲烷中,在0℃下加入2倍体积的三氟乙酸,继续搅拌2h,LC-MS监测反应完全。在旋转蒸发仪上除去二氯甲烷和三氟乙酸,并在真空泵下干燥2h以除去残留的溶剂和酸。粗产物(38.8mg)可不需要进一步纯化直接用于下一步,LC-MS:m/z=432.1。
将11-6(10.8mg,25mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(17mg,0.045mmol,2.0equiv),5分钟后,依次加入DIEA(8.6mg,0.065mmol,3.0equiv)和化合物1(10mg,0.023mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干。粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物7.9mg,产率40%,LC-MS:m/z=862.3。
NMR:1H NMR(400MHz,CDCl3)δ7.86(d,J=1.8Hz,1H),7.76–7.64(m,2H),7.54(s,1H),7.51–7.42(m,2H),7.41–7.35(m,2H),7.24(dd,J=8.4,4.4Hz,1H),7.11(d,J=7.9Hz,1H),5.33(s,1H),5.13(s,2H),5.02–4.93(m,1H),4.76–4.57(m,2H),4.34–4.15(m,2H),4.13–3.92(m,2H),3.85–3.66(m,1H),3.39–3.20(m,2H),3.20–3.00(m,2H),2.92–2.64 (m,6H),2.29–2.11(m,4H),1.79–1.72(m,5H),1.66(s,6H).
实施例14化合物C14的制备
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(100mg,0.4mmol,1.0equiv),碘化钾(6.1mg,0.03mmol,0.1equiv)和碳酸氢钠(61.3mg,0.4mmol,2.0equiv)溶于DMF中,向反应体系中加入5-溴-1-戊醇(80.2mg,0.48mmol,1.2equiv)。之后将反应体系加热至80℃,反应过夜。终止加热,待反应体系降至室温,加入适量乙酸乙酯稀释,并用饱和食盐水萃取5 次,取有机相加入无水硫酸钠干燥,过滤,旋干。粗产物通过硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2)。得终产物110.7mg,产率64%,LC-MS:m/z=361.1。
将12-1(110.7mg,0.31mmol,1.0equiv),PCC(133.7mg,0.62mmol,2.0equiv)溶于适量二氯甲烷中,室温搅拌6h。向反应体系中加入适量硅胶,旋干,硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2),得终产物108.9mg,产率98%,LC-MS:m/z=359.1。
将12-2(108.9mg,0.3mmol,1.0equiv),oxone(175.1mg,0.3mol,1.0equiv)溶于适量DMF 中,室温搅拌过夜。向反应体系加入乙酸乙酯稀释并用水和饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,过滤,旋干,得终产物88.7mg,产率79%,LC-MS:m/z=375.1。
将12-3(52.4mg,0.14mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(105.8mg,0.28mmol,2.0equiv),5分钟后,依次加入DIEA(71.5mg,0.56mmol,4.0equiv)和Β-丙氨酸叔丁酯盐酸盐(25.4mg,0.14mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,粗产物通过硅胶柱层析进行纯化,得终产物47mg,产率67%,LC-MS: m/z=502.2。
将12-4(47mg,0.09mmol)溶于适量二氯甲烷中,在0℃下加入2倍体积的三氟乙酸,继续搅拌2h,LC-MS监测反应完全。在旋转蒸发仪上除去二氯甲烷和三氟乙酸,并在真空泵下干燥2h以除去残留的溶剂和酸,粗产物(40.1mg)可不需要进一步纯化直接用于下一步,LC-MS:m/z=446.2。
将12-5(11.1mg,0.025mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(17mg,0.045mmol,2.0equiv),5分钟后,依次加入DIEA(8.6mg,0.065mmol,3.0equiv)和化合物1(10mg,0.023mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干。粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物9.4mg,产率43%,LC-MS:m/z=876.2。
NMR:1H NMR(400MHz,CDCl3)δ7.86(s,1H),7.75–7.63(m,2H),7.54(s,1H),7.51–7.42(m,2H),7.42–7.34(m,2H),7.24(d,J=8.6Hz,1H),7.12(s,1H),5.46(d,J=16.4Hz,1H),5.12(s,2H),5.04–4.94(m,1H),4.68(dd,J=33.0,13.7Hz,2H),4.31–4.16(m,2H),4.00(dd,J=26.4,13.7Hz,2H),3.83–3.68(m,1H),3.35–3.19(m,2H),3.18–3.03(m,1H),3.01–2.65(m,6H),2.51–2.30(m,3H),2.26–2.10(m,4H),1.80–1.74(m,5H),1.65(s,6H).
实施例15化合物C15的制备
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(100mg,0.4mmol,1.0equiv),碘化钾(6.1mg,0.03mmol,0.1equiv)和碳酸氢钠(61.3mg,0.4mmol,2.0equiv)溶于DMF中,向反应体系中加入6-溴-1-己醇(86.9mg,0.48mmol,1.2equiv)。之后将反应体系加热至80℃,反应过夜。终止加热,待反应体系降至室温,加入适量乙酸乙酯稀释,并用饱和食盐水萃取5 次,取有机相加入无水硫酸钠干燥,过滤,旋干。粗产物通过硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2),得终产物120.4mg,产率67%,LC-MS:m/z=375.2。
将13-1(120.4mg,0.32mmol,1.0equiv),PCC(138mg,0.64mmol,2.0equiv)溶于适量二氯甲烷中,室温搅拌6h。向反应体系中加入适量硅胶,旋干,硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2),得终产物118mg,产率99%,LC-MS:m/z=373.1。
将13-2(118mg,0.32mmol,1.0equiv),oxone(186.8mg,0.32mol,1.0equiv)溶于适量DMF 中,室温搅拌过夜。向反应体系加入乙酸乙酯稀释并用水和饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,过滤,旋干,得终产物100.7mg,产率81%,LC-MS:m/z=389.1。
将13-3(54.4mg,0.14mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(105.8mg,0.28mmol,2.0equiv),5分钟后,依次加入DIEA(71.5mg,0.56mmol,4.0equiv)和Β-丙氨酸叔丁酯盐酸盐(25.4mg,0.14mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,粗产物通过硅胶柱层析进行纯化,得终产物42.6mg,产率59%,LC-MS:m/z=516.3。
将13-4(42.6mg,0.08mmol)溶于适量二氯甲烷中,在0℃下加入2倍体积的三氟乙酸,继续搅拌2h,LC-MS监测反应完全。在旋转蒸发仪上除去二氯甲烷和三氟乙酸,并在真空泵下干燥2h以除去残留的溶剂和酸。粗产物(36.8mg)可不需要进一步纯化直接用于下一步,LC-MS:m/z=460.2。
将13-5(11.5mg,0.025mmol,1.0equiv)溶于适量DMF中,0℃下搅拌,加入 HBTU(17mg,0.045mmol,2.0equiv),5分钟后,依次加入DIEA(8.6mg,0.065mmol,3.0equiv)和化合物1(10mg,0.023mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋转蒸发仪除去多余溶剂。粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物10.4mg,产率51%,LC-MS:m/z=890.3。
NMR:1H NMR(400MHz,CDCl3)δ7.87(s,1H),7.76–7.63(m,2H),7.53(s,1H),7.49–7.41(m,2H),7.41–7.33(m,2H),7.24(d,J=8.5Hz,1H),7.10(s,1H),5.32(s,1H),5.24(d,J=11.7Hz,1H),5.11(s,2H),5.05(s,1H),5.02–4.91(m,1H),4.75–4.57(m,2H),4.26–4.15(m,2H),4.00(dd,J=27.7,14.5Hz,2H),3.84–3.64(m,1H),3.34–3.20(m,2H),3.17–3.05(m,1H),2.96–2.63(m,6H),2.45–2.31(m,3H),2.30–2.09(m,4H),1.91–1.71(m,9H), 1.65(s,6H).
实施例16化合物C16的制备
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(100mg,0.4mmol,1.0equiv),碘化钾(6.1mg,0.03mmol,0.1equiv)和碳酸氢钠(61.3mg,0.4mmol,2.0equiv)溶于DMF中,向反应体系中加入7-溴-1-庚醇(93.6mg,0.48mmol,1.2equiv)。之后将反应体系加热至80℃,反应过夜。终止加热,待反应体系降至室温,加入适量乙酸乙酯稀释,并用饱和食盐水萃取5 次,取有机相加入无水硫酸钠干燥,过滤,旋干。粗产物通过硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2),得终产物113.7mg,产率61%,LC-MS:m/z=389.1。
将14-1(113.7mg,0.29mmol,1.0equiv),PCC(125mg,0.58mmol,2.0equiv)溶于适量二氯甲烷中,室温搅拌6h。向反应体系中加入适量硅胶,旋干,硅胶柱层析进行纯化(V(石油醚):V(乙酸乙酯)=1:2),得终产物110.9mg,产率99%,LC-MS:m/z=387.2。
将14-2(110.9mg,0.29mmol,1.0equiv),oxone(180.6mg,0.29mol,1.0equiv)溶于适量DMF 中,室温搅拌过夜。向反应体系加入乙酸乙酯稀释并用水和饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,过滤,旋干,得终产物99.2mg,产率85%,LC-MS:m/z=403.2。
将14-3(54.4mg,0.14mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入HBTU(105.8mg, 0.28mmol,2.0equiv),5分钟后,依次加入DIEA(71.5mg,0.56mmol,4.0equiv)和Β-丙氨酸叔丁酯盐酸盐(25.4mg,0.14mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干。粗产物通过硅胶柱层析进行纯化,得终产物47.5mg,产率64%,LC-MS:m/z=530.3。
将14-4(47.5mg,0.09mmol)溶于适量二氯甲烷中,在0℃下加入2倍体积的三氟乙酸,继续搅拌2h,LC-MS监测反应完全。在旋转蒸发仪上除去二氯甲烷和三氟乙酸,并在真空泵下干燥2h以除去残留的溶剂和酸。粗产物(42.6mg)可不需要进一步纯化直接用于下一步,LC-MS:m/z=474.2。
将14-5(11.8mg,0.025mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入HBTU(17mg,0.045mmol,2.0equiv),5分钟后,依次加入DIEA(8.6mg,0.065mmol,3.0equiv)和化合物 1(10mg,0.023mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋转蒸发仪除去多余溶剂。粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物8.1mg,产率39%,LC-MS:m/z=904.3。
NMR:1H NMR(400MHz,MeOD)δ7.76(s,1H),7.71(d,J=8.4Hz,2H),7.55(s,1H),7.52–7.43(m,2H),7.42–7.35(m,3H),7.30(s,1H),5.37–5.31(m,2H),5.20(s,2H),5.08(dd,J=12.1,4.9Hz,2H),4.61–4.51(m,2H),4.42(dd,J=9.7,3.9Hz,1H),4.25–4.19(m,2H),4.05–3.98(m,1H),3.81–3.72(m,2H),3.64–3.56(m,3H),3.50–3.45(m,2H),2.87–2.62(m,6H),2.60–2.52(m,2H),2.49–2.41(m,2H),2.15–2.03(m,5H),1.56(s,6H).
实施例17化合物C17的制备
将1-叔丁氧羰基-4-哌啶乙酸(50.4mg,0.22mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入HBTU(166.2mg,0.44mmol,2.0equiv),5分钟后,依次加入DIEA(84.3mg,0.66mmol,3.0 equiv)和化合物1(100mg,0.22mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干。粗产物通过硅胶柱层析进行纯化,得终产物117.2mg,产率81%,LC-MS: m/z=660.3。
称取15-1(117.2mg,0.18mmol)至圆底烧瓶,加入4M的盐酸二氧六环溶液,室温搅拌至反应完全。旋转蒸发除去多余溶剂,得到黄色固体即为盐酸盐形式的终产物103.1mg,产率96%,LC-MS:m/z=560.3。
将12-3(9.4mg,0.025mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入HBTU(17mg,0.045mmol,2.0equiv),5分钟后,依次加入DIEA(8.6mg,0.065mmol,3.0equiv)和15-2(13mg,0.023mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋转蒸发仪除去多余溶剂。粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物7.4mg,产率35%,LC-MS:m/z=916.4。
NMR:1H NMR(400MHz,MeOD)δ7.75(s,1H),7.73–7.66(m,2H),7.55(s,1H),7.51–7.45(m,1H),7.41–7.33(m,4H),7.29(d,J=1.8Hz,1H),5.20(s,2H),5.09(dd,J=12.9,5.0Hz,1H),4.58(d,J=14.7Hz,1H),4.25–4.15(m,2H),4.04(d,J=13.4Hz,1H),3.49(t,J=6.5Hz,2H),3.31–3.19(m,5H),2.92–2.65(m,6H),2.65–2.54(m,2H),2.34(t,J=6.7Hz,2H),2.21–2.07(m,5H),1.91–1.80(m,4H),1.79–1.61(m,3H),1.56(s,6H).
实施例18化合物C18的制备
将13-3(11.7mg,0.03mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(22.7mg,0.045mmol,2.0equiv),5分钟后,依次加入DIEA(11.9mg,0.065mmol,3.0equiv)和15-2(17mg,0.03mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋转蒸发仪除去多余溶剂。粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物14.2mg,产率51%,LC-MS:m/z=930.3。
NMR:1H NMR(400MHz,CDCl3)δ10.68(d,J=59.9Hz,1H),7.83(s,1H),7.68–7.59(m,2H),7.48(s,1H),7.45–7.28(m,4H),7.19(d,J=8.5Hz,1H),7.05(s,1H),6.69(t,J=6.1 Hz,1H),5.18(d,J=8.2Hz,2H),5.05(s,2H),5.00–4.92(m,1H),4.69–4.56(m,1H),4.26– 4.09(m,2H),3.89(d,J=13.8Hz,1H),3.68–3.53(m,1H),3.52–3.36(m,1H),3.28–3.07(m, 2H),2.92–2.66(m,5H),2.54(t,J=5.5Hz,2H),2.30–2.04(m,6H),1.88–1.77(m,3H),1.76 –1.64(m,5H),1.61(s,6H),1.58–1.46(m,3H);13C NMR(100MHz,CDCl3)δ173.24,172.30, 172.19,170.14,169.08,167.15,165.92,156.56,150.34,141.09,136.88,136.67,136.48,136.00, 135.72,133.80,131.66,130.88,128.79,127.43,123.43,119.38,117.61,117.41,115.89,115.00, 94.86,81.42,69.99,69.30,65.40,49.25,45.14,41.55,40.55,36.54,35.05,33.04,32.76,32.14, 31.58,31.49,28.23,25.62,25.09,22.71.
实施例19化合物C19的制备
将14-3(12.1mg,0.03mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(22.7mg,0.045mmol,2.0equiv),5分钟后,依次加入DIEA(11.9mg,0.065mmol,3.0equiv)和15-2(17mg,0.03mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋转蒸发仪除去多余溶剂。粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:20),得终产物15.1mg,产率53%,LC-MS:m/z=944.4。
NMR:1H NMR(400MHz,CDCl3)δ10.93(d,J=86.1Hz,2H),7.79(s,1H),7.69–7.55(m,2H),7.44(s,1H),7.42–7.27(m,4H),7.16(d,J=8.5Hz,1H),7.02(s,1H),6.92–6.77(m,1H),5.20(s,2H),5.02(s,2H),4.99–4.92(m,1H),4.61(d,J=12.6Hz,1H),4.23–4.05(m,2H),3.83(d,J=13.9Hz,1H),3.62(dt,J=13.0,6.5Hz,4H),3.53–3.44(m,1H),3.22–3.01(m,5H),2.87–2.70(m,4H),2.61–2.42(m,3H),2.20–2.02(m,5H),1.87–1.74(m,2H), 1.73–1.61(m,3H),1.58(s,6H),1.53–1.51(m,3H);13C NMR(100MHz,CDCl3)δ173.45, 172.27,172.16,170.26,169.32,167.16,165.82,156.59,150.31,141.09,136.85,136.66,136.47,136.04,135.72,133.82,131.65,130.85,128.78,127.44,123.44,119.03,117.62,117.18,115.70, 114.97,94.92,81.39,69.95,69.25,65.35,49.21,45.07,41.59,40.44,35.94,34.94,32.98,32.61, 32.07,31.59,31.49,28.34,28.20,25.25,25.01,22.77.
实施例20化合物C20的制备
将2-(2,6-二氧代哌啶-3-基)-4-羟基异-1,3-二酮(200mg,0.73mmol,1.0equiv)和碳酸氢钠(184mg,2.19mmol,3.0equiv)溶于DMF中,向反应体系中逐滴加入3-(2-碘乙氧基)丙-1-炔(184mg,0.88mmol,1.2equiv)。加热反应体系至80℃,搅拌过夜。待反应完全后,加入适量乙酸乙酯稀释,并依次用水和饱和碳酸氢钠溶液的混合液(V(水):V(饱和碳酸氢钠溶液)=1:5),饱和食盐水萃取。取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,硅胶柱层析纯化(V(丙酮):V(石油醚)=1:2),得终产物156.1mg,产率70%, LC-MS:m/z=357.2。
取硫酸铜(14.4mg,0.09mmol,0.2equiv)溶于6mL水中。取16-1(156.1mg,0.44mmol,1 equiv)和2-叠氮基-1,1-二乙氧基乙烷(70mg,0.44mmol,1equiv)分别溶于6mL叔丁醇中,并依次加入硫酸铜溶液中。将抗坏血酸钠(35.6mg,0.18mmol,0.4equiv)溶于6mL水中,并加入反应体系。反应体系于室温搅拌过夜。监测反应完全后,加入饱和食盐水稀释反应液,并用氯仿萃取两次。合并有机相,依次用饱和碳酸氢钠溶液,饱和食盐水萃取。向有机相中加入无水硫酸钠干燥,与旋转蒸发仪上除去多余溶剂得粗产物。经硅胶柱层析纯化,得终产物102.1mg,产率45%,LC-MS:m/z=516.2。
将16-2(100mg,0.19mmol)加入4M盐酸二氧六环溶液,并滴入少量水。反应体系升温至60℃,TLC监测至反应完全,旋蒸除去多余溶剂。加入适量乙酸乙酯稀释,并用饱和食盐水萃取两次得终产物25.1mg,产率30%,LC-MS:m/z=442.2。
将16-3(25mg,0.06mmol,1.0equiv),oxone(37mg,0.32mmol,1.0equiv)溶于适量DMF 中,室温搅拌过夜。向反应体系加入乙酸乙酯稀释并依次用水和饱和食盐水萃取3次,取有机相加入无水硫酸钠干燥,过滤,旋干,得终产物23mg,产率83%,LC-MS:m/z=458.1。
将16-4(22.9mg,0.05mmol,1.0equiv)溶于适量DMF中,0℃搅拌,加入 HBTU(34mg,0.09mmol,2.0equiv),5分钟后,依次加入DIEA(17.2mg,0.13mmol,3.0equiv)和化合物1(20mg,0.045mmol,1.0equiv),升温至室温,搅拌过夜。向反应体系中加入乙酸乙酯稀释并用水和饱和食盐水萃取三次,取有机相加入无水硫酸钠干燥,砂芯漏斗抽滤,旋干,粗产物通过硅胶柱层析进行纯化(V(甲醇):V(二氯甲烷)=1:10),得终产物16.0mg,产率40%,LC-MS:m/z=888.3。
NMR:1H NMR(400MHz,MeOD)δ7.96(d,J=3.8Hz,1H),7.78(d,J=1.8Hz,1H),7.74–7.65(m,2H),7.52(s,1H),7.47(d,J=7.3Hz,1H),7.41–7.38(m,3H),7.29(dd,J=8.5, 1.7Hz,1H),7.12(d,J=1.8Hz,1H),5.34(p,J=16.3Hz,2H),5.12(s,2H),5.05–4.93(m, 1H),4.84(q,J=12.7Hz,2H),4.57(d,J=13.4Hz,1H),4.45–4.30(m,2H),3.47–3.22(m, 4H),3.06–2.72(m,5H),2.35–2.00(m,4H),1.96–1.66(m,3H),1.60(s,6H);13C NMR(101MHz,MeOD)δ171.84,171.64,168.66,166.66,165.35,163.22,155.72,149.85,144.35,140.81, 136.11,135.86,135.65,135.26,133.01,131.03,130.12,128.13,126.74,124.69,123.01,118.87, 116.71,116.50,115.50,114.49,94.15,80.41,69.45,68.50,67.50,64.30,64.02,50.29,44.44, 41.62,39.57,39.46,31.64,31.18,30.72,30.50,22.02.
实施例21生物学实验
S1:复苏Jurkat细胞,贴壁培养12h,加入化合物,化合物浓度固定(处理时间为0、3、6、12、24和72h)或者处理时间固定(化合物物浓度为0、1、10、100、1000nM);
S2:倒掉培养液,加入3ml4℃预冷的PBS洗涤细胞后弃去洗液,根据细胞量加入适量含PMSF(100×)的裂解液,混合均匀置于冰上裂解30min,于4℃下12000rpm离心5min,(提前开离心机预冷),将离心后的上清转移倒新的离心管中,准备定量;
S3:取PierceTMBCA Protein Assay Kit(23225)的BCA定量试剂,200ul/well,再加入 20ul已知的不同浓度的BSA以制备蛋白定量标准曲线及待测样品蛋白,避免产生气泡,37℃避光孵育30min后,检测562nm条件下的OD值,向蛋白样品中加入适量SDS-PAGEloading buffer,沸水浴加热5分钟,以充分变性蛋白,-20℃保存备用;
S4:配制SDS-PAGE凝胶,浓缩胶的电压为90V,分离胶的电压为120V,4℃条件下,100V电压转膜1h,转膜完毕后,立即把蛋白膜放置预先准备好的5%BSA溶液中,在摇床上缓慢摇动,室温封闭1h;
S5:参考HPK1 Antibody(4472SCST)、GLK(D1L4G)Rabbit mAb(92427S CST)、 SLP-76(D1R1A)Rabbit mAb(70896S CST)、Phospho-SLP-76(Ser376)(D7S1K)Rabbit mAb(92711TCST)、β-actin Mouse Monoclonal antibody(BE0021 easybio)的说明书,按照适当比例稀释一抗,4℃缓慢摇动孵育过夜,再用PBST洗涤3次,10min/次;
S6:根据一抗选择Goat Anti-Rabbit IgG(H&L)-HRP Conjugated(BE0101easybio)或Goat Anti-Mouse IgG(H&L)-HRP Conjugated(BE0102 easybio),参考二抗的说明书,按照适当比例稀释二抗,室温缓慢摇动孵育1h,用PBST洗涤3次,10min/次;
S7:加入ECL发光液,通过显影仪观察结果,利用Image J软件对Western结果进行定量,通过与不加化合物的对照组进行对比计算降解率(HPK1和GLK)或者抑制率(SLP76Ser376磷酸化),(降解率/抑制率=1-加药组/对照组)。实验结果如下表所示。
表1固定处理时间为12h,改变化合物处理浓度HPK1的降解率
化合物 | 降解率(10nM) | 降解率(100nM) |
C1 | 47% | 68% |
C2 | 39% | 33% |
C3 | 15% | 75% |
C7 | 72% | 68% |
表2 100nM化合物处理浓度,在不同时间条件下HPK1的降解率
表3固定化合物处理浓度为100nM、在不同时间点下HPK1最大降解率和SLP-76 磷酸化的最大抑制率
化合物 | HPK1最大降解率 | SLP76 Ser376磷酸化最大抑制率 |
C3 | 62% | 81% |
表4 100nM化合物处理6h时HPK1、GLK降解率和SLP-76磷酸化抑制率
化合物 | HPK1降解率 | GLK降解率 | SLP76磷酸化抑制率 |
C8 | 66% | 34% | 51% |
C9 | 46% | -34% | 61% |
C10 | 48% | -30% | |
C11 | 30% | -36% | |
C12 | 30% | 22% | |
C13 | 38% | 43% | 4% |
C14 | 58% | 60% | 26% |
C15 | -27% | 38% | -7% |
C16 | 49% | 74% | 24% |
C17 | -7% | 42% | 22% |
C18 | 39% | 71% | 34% |
C19 | -95% | 34% | 3% |
C20 | -15%(12h41%) | 15% | 7% |
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (26)
1.一种通式为Ⅰ的化合物,或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物:
其中,MAP4Ks家族抑制剂选自:HPK1抑制剂、MAP4K2抑制剂、MAP4K3抑制剂、MAP4K4抑制剂、MAP4K5抑制剂、MAP4K6抑制剂;
q选自1-5之间的整数;
Cereblon蛋白配体为E3泛素连接酶复合体中Cereblon蛋白的小分子配体;
L是Cereblon蛋白配体与MAP4Ks家族抑制剂之间的连接基团;
优选的,所述的L为-A1-A2……-At-,
A1,A2……At独立的选自:
CRL1RL2、O、S、S=O、S(=O)2、S(O)2O、OS(O)2、OS(O)2O、NRL3、S(=O)2NRL3、S(=O)NRL3、C(=O)NRL3、OC(O)NRL3、NRL3C(=O)、NRL3C(=O)NRL4、NRL3S(=O)2NRL4、C(=O)、CRL1=CRL2、C=C、C≡C、SiRL1RL2、P(=O)RL1、P(=O)ORL1、NRL3C(=N-CN)NRL4、NRL3C(=N-CN)、NRL3C(=C-NO2)NRL4、C3-11环烃基、C3-11杂环烃基、琥珀酰亚胺基、-CH2CH2O-、-OCH2CH2-、或不存在,其中,所述的环烃基、杂环烃基中任意氢原子可被1-6个RL1或RL2取代;
当A1,A2……At为CRL1RL2或SiRL1RL2时,RL1、RL2独立地可以与其它A连接形成环烃基或杂环烃基,优选的,所述的环烃基或杂环烃基任选地被1-11个RL5基团取代;
RL1、RL2、RL3、RL4、RL5独立的选自H、卤素、C1-8烷基、O(C1-8烷基)、S(C1-8烷基)、NH(C1-8烷基)、N(C1-8烷基)2、C3-11环烃基、C3-11杂环烃基、O(C1-8环烃基)、S(C1-8环烃基)、NH(C1-8环烃基)、N(C1-8环烃基)(C1-8烷基)、OH、NH2、SH、SO2(C1-8烷基)、P(=O)(OC1-8烷基)(C1-8烷基)、P(=O)(OC1-8烷基)2、C1-8炔基、CH=CH(C1-8烷基)、C(C1-8烷基)=CH(C1-8烷基)、C(C1-8烷基)=C(C1-8烷基)2、Si(OH)3、Si(C1-8烷基)3、Si(OH)(C1-8烷基)2、C(=O)(C1-8烷基)、CO2H、CN、CF3、CHF2、CH2F、NO2、SF5、SO2NH(C1-8烷基)、SO2N(C1-8烷基)2、S(=O)N(C1-8烷基)2、C(=O)NH(C1-8烷基)、C(=O)N(C1-8烷基)2、N(C1-8烷基)C(=O)NH(C1-8烷基)、N(C1-8烷基)C(=O)N(C1-8烷基)2、NHC(=O)NH(C1-8烷基)、NHC(=O)N(C1-8烷基)2、NHC(=O)NH2、N(C1-8烷基)SO2NH(C1-8烷基)、N(C1-8烷基)SO2N(C1-8烷基)2、NHSO2NH(C1-8烷基)、NHSO2N(C1-8烷基)2或NHSO2NH2;
X3选自O、S、-NR-、-CHR-;
R选自H或被1个或2个-OH取代的C1-3烷基;
i选自1-6之间的整数;
Y选自-O-、-S-、-NR-或不存在;
t选自1-100之间的整数,优选的,t选自1-50的整数。
2.如权利要求1所述的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物,其特征在于,所述MAP4Ks家族抑制剂选自:HPK1抑制剂。
6.根据权利要求5所述的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物,其特征在于,C1、C2、C3、C4选自C;或者,当C1为C时,C2、C3、C4至少一个为N;或者,当C2为C时,C1、C3、C4至少一个为N;或者,当C3为C时,C1、C2、C4至少一个为N;或者,当C4为C时,C1、C2、C3至少一个为N。
11.根据权利要求1所述的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物,其特征在于,所述的HPK1抑制剂的通式如下:
上述HPK1通式与Cereblon蛋白配体的连接位点有3个、2个、1个,可任意连接3个、2个或1个Cereblon蛋白配体,其余连接位点用-R”’代替;优选的,HPK1抑制剂中①位、②位和③位均是Cereblon蛋白配体的连接位点,或者,①位和②位是Cereblon蛋白配体的连接位点,③位连接R”’,或者,②位和③位是Cereblon蛋白配体的连接位点,①位连接R”’,或者,①位和③位是Cereblon蛋白配体的连接位点,②位连接R”’,或者,①位是Cereblon蛋白配体的连接位点,②位和③位连接R”’,或者,②位是Cereblon蛋白配体的连接位点,①位和③位连接R”’,或者,③位是Cereblon蛋白配体的连接位点,①位和②位连接R”’,或者,①位和②位是Cereblon蛋白配体的连接位点,或者,①位是Cereblon蛋白配体的连接位点,②位连接R”’,或者,②位是Cereblon蛋白配体的连接位点,①位连接R”’;
其中,R”’选自-H、卤素、-NO2、-CN、C1-5直链/支链烷基、C3-10环烃基、-N(C0-10烷基)(C0-10烷基)、-CF3、-OCF3、-OCHF2、-OCH2F或-OC0-10烷基;
A选自C或N;B选自C或N;
所述Q选自O或S;x和z独立的选自0-6间的整数;y选自0或1;
所述R0独立的选自:-H、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基或C3-10环烃基;
所述R1选自-O杂环烷基、-N杂环烷基、C1-10直链/支链烷基、C3-10环烷基、-OC0-10烷基、-N(C0-10烷基)(C0-10烷基)、-SO2(C0-10烷基)、-O(C0-10烷基)、-O-苯基、-S(C0-10烷基)、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基,其中C原子或杂原子上的H可被C1-3直链烷基、-N(C0-10烷基)(C0-10烷基)、-CF3取代;
所述R2选自:-H、卤素、-NO2、-CN、C1-5直链/支链烷基、C3-10环烃基、-N(C0-10烷基)(C0-10烷基)、-CF3、-OCF3、-OCHF2、-OCH2F或-OC0-10烷基;
当B为N时,R3不存在;当B为C时,所述R3选自:-H、卤素、-OC0-10烷基、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)或C3-10环烃基;
所述R4选自:-H、卤素、-OC0-10烷基、-CN、C3-10环烃基、-C≡C-R10、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-O杂环烃基或-N杂环烃基;
所述R11、R12独立的选自:-H、-CF3、-CHF2H、-CH2F、C1-10直链/支链烷基、-CH=C(C0-10烷基)(C0-10烷基)、-C≡C(C0-10烷基)、C3-10环烃基、芳香性五元环基团或芳香性六元环基团,或R11、R12与R11和R12之间的碳原子形成C3-8环烃基或含-O、-S的C3-8杂环烃基,C9稠环烃基、C3-7环内酰胺、C3-7环内酯、C3-7环酮,其中C原子上的H可被烷基或卤素取代;
R5选自:-H、卤素、-CN、-OC0-10烷基、C1-10直链/支链烷基、含O或N的杂烷基、-N(C0-10烷基)(C0-10烷基)、C3-10环烃基、-C≡C-R10、-O杂环烃基或-N杂环烃基,其中C原子上的H可被以下基团取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、-N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、-OCH2F、-OCHF2、-OCF3、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、C3-10环烃基、-O杂环烷基、-N杂环烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基;
R8和R9独立的选自:-H、卤素、C1-10直链/支链烷基;
A'选自C或N;B1、B2、B3、B4或B5独立的选自C或N;
Q'选自O或S;x'和z'独立的选自0-6间的整数;y'选自0或1;
所述R0'独立的选自:-H、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基或C3-10环烃基;
所述R1'选自:-O杂环烷基、-N杂环烷基、C1-10直链/支链烷基、C3-10环烃基、-OC0-10烷基、-N(C0-10烷基)(C0-10烷基)、-SO2(C0-10烷基)、-O(C0-10烷基)、-O-苯基、-S(C0-10烷基)、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基,其中C原子或杂原子上的H可被C1-3直链烷基、-N(C0-10烷基)(C0-10烷基)、-CF3取代;
所述R2'选自:-H、卤素、-NO2、-CN、C1-5直链/支链烷基、C3-10环烃基、-N(C0-10烷基)(C0-10烷基)、-CF3、-OCF3、-OCHF2、-OCH2F或-OC0-10烷基;
当B1、B2、B3、B4或B5为N时,其所对应的R3'、R4'、R5'不存在;当B1、B2、B3、B4或B5为C时,所述R3'、R4'、R5'独立的选自:-H、卤素、-CN、-OC0-10烷基、C1-10直链/支链烷基、含O或N的杂烷基、-N(C0-10烷基)(C0-10烷基)、C3-10环烃基、-C≡C-R10'、-O杂环烃基、-N杂环烃基,或R5'和R4'、R4'和R3'与其之间的碳原子形成C3-8环烃基或含-O-、-S-的C3-8杂环烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基、苯基,其中C原子上的H可被以下基团取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、-N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、-OCH2F、-OCHF2、-OCF3、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、C3-10环烃基、-O杂环烷基、-N杂环烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基;
R8'和R9'独立的选自:-H、卤素、C1-10直链/支链烷基;R35、R36、R38、R39选自C1-10直链/支链烷基、-CON(C0-10烷基)-、-CO(C0-10烷基)-、C3-10环烃基、-O杂环烷基、-N杂环烷基、苯基、-N杂环芳香基、-O杂环芳香基,R37与相连的N原子及N相邻的C原子形成5-8元环内酰胺;
R13-R34独立的选自:-H、卤素、-CN、-OC0-10烷基、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、C3-10环烃基、-O杂环烷基、-N杂环烷基、-S杂环烷基、苯基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基。
13.根据权利要求12所述的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物,其特征在于,所述R0独立的选自:C1-5直链/支链烷基或-N(C0-10烷基)(C0-10烷基);
所述R1选自:-O杂环烷基或-N杂环烷基、-SO2(C0-3烷基)、-O-苯基、-S(C0-4烷基)、C3-6环烷基或C3-5直链/支链烷基,其中C原子或杂原子上的H可被-CH3、-NH2、-CF3取代;
所述R2选自:-NO2、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基或-OCF3;
所述R3选自:-H、卤素、-OC0-10烷基、C1-10直链/支链烷基;
所述R4选自:-H、卤素、-OC0-10烷基、-CN、C3-10环烷基或-C≡C-R10;
所述R11、R12独立的选自:-H、-CF3、-CHF2H、-CH2F、C1-10直链/支链烷基、-CH=C(C0-10烷基)(C0-10烷基)、C3-10环烷基或芳香性六元环基团,或R11、R12与R11和R12之间的碳原子形成C3-8环烷基、C4-7稠环烷基、C3-7环内酰胺、C3-7环内酯、C3-7环酮,其中C原子上的H可被烷基或-F取代;
所述R5选自:-H、卤素、C3-6环烷基、-OC0-5烷基、C1-5直链/支链烷基、含O或N的C1-5直链/支链烷基,其中C原子上的H可被-F取代;
所述R8和R9独立的选自:-H、C1-10直链/支链烷基。
14.根据权利要求13所述的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物,其特征在于,R0独立的选自:-CH3、-CH2CH3或-NH2;
所述R2选自:-NH2或-NO2;
所述R3选自:-H、-F或-OCH3;
所述R5选自:-H、卤素、-OC0-3烷基、C1-3直链/支链烷基、含N的C1-3直链/支链烷基,其中C原子上的H可被-F取代,优选的,所述R5选自:-H、-F、-Cl、-CH3、-CH2NH2、-CN、-OCH3;
所述R8和R9独立的选自:-H或-CH3。
15.根据权利要求11所述的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物,其特征在于,所述B1、B2、B3、B4或B5为C,或者,所述B1、B2、B3、B4或B5中至少一个为N;
优选的,所述的B2为C,所述的B1、B3、B4或B5中至少一个为N,或者,所述的B2为C,所述的B1为N;所述的B2为C,所述的B3为N;所述的B2为C,所述的B4为N;所述的B2为C,所述的B5为N,或者,所述的B2为C,B3和B4为N或者B3和B5中为N;
x'和z'独立的选自0-2间的整数,如0、1或2;
所述HPK1抑制剂结构式为:
所述R0'独立的选自:C1-5直链/支链烷基或-N(C0-10烷基)(C0-10烷基);
所述R1'选自:-O杂环烷基或-N杂环烷基、-SO2(C0-3烷基)、-O-苯基、-S(C0-4烷基)、C3-6环烷基或C3-5直链/支链烷基,其中C原子或杂原子上的H可被-CH3、-NH2、-CF3取代;
所述R2'选自:-NO2、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基或-OCF3;
所述R3'选自:-H、卤素、-OC0-10烷基、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)或C3-10环烷基;
所述R4'选自:-H、卤素、-OC0-10烷基、-CN、C3-10环烷基、-C≡C-R10'、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-O杂环烷基或-N杂环烷基;
R5'独立的选自:-H、卤素、-CN、-OC0-10烷基、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、C3-10环烷基、-C≡C-R10'、-O杂环烷基或-N杂环烷基、含O或N的C1-5直链/支链烷基,其中C原子上的H可被-F取代;
所述R11'、R12'独立的选自:-H、-CF3、-CHF2H、-CH2F、C1-10直链/支链烷基、-CH=C(C0-10烷基)(C0-10烷基)、-C≡C(C0-10烷基)、C3-10环烷基、芳香性五元环基团或芳香性六元环基团,或R11、R12与R11和R12之间的碳原子形成C3-8环烷基或含-O、-S的C3-8杂环烷基、C4-9稠环烷基、C5-10螺环烷基、C4-9桥环烷基、C3-7环内酰胺、C3-7环内酯、C3-7环酮,其中C原子上的H可被以下基团取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、-N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、-OCH2F、-OCHF2、-OCF3、C1-10直链/支链烷基、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、C3-10环烷基、-O杂环烷基、-N杂环烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基,其中所述烷基部分可被一个或多个以下基团任意取代:-SO2、-SO2N(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)SO2(C0-10烷基)、-CON(C0-10烷基)(C0-10烷基)、-N(C0-10烷基)CO(C0-10烷基)、-N(C0-10烷基)COO(C0-10烷基)、-OCON(C0-10烷基)(C0-10烷基)、卤素、-CN、-OCH2F、-OCHF2、-OCF3、-N(C0-10烷基)(C0-10烷基)、-OC0-10烷基、-N杂环芳香基、-O杂环芳香基或-S杂环芳香基;
所述R8'和R9'独立的选自:-H、C1-10直链/支链烷基。
16.根据权利要求15所述的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物,其特征在于,R0'独立的选自:-CH3、-CH2CH3或-NH2;
所述R2'选自:-NH2或-NO2;
所述R3'选自:-H、卤素、-OC0-10烷基、C1-10直链/支链烷基;
所述R5'选自:-H、-F、-Cl、-CH3、-CH2NH2、-CN、-OCH3;
所述R8'和R9'独立的选自:-H或-CH3。
20.一种药物组合物,所述药物组合物包含权利要求1所述的通式Ⅰ的化合物或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物,还包括药剂学上可接受的辅料。
21.一种权利要求1所述的通式Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物在制备抑制丝氨酸/苏氨酸激酶家族的药物中的应用,优选的,在制备抑制造血干细胞激酶1的药物中的应用。
22.一种权利要求1所述的通式Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物在制备治疗与造血干细胞激酶1相关的疾病的药物中的应用,所述的与造血干细胞激酶1相关的疾病选自:炎症、免疫疾病、癌症,
所述免疫疾病选自:红斑狼疮、血管球性肾炎、类风湿性关节炎、牛皮癣、炎症性肠病和自身免疫糖尿病;
所述癌症选自:淋巴瘤、母细胞瘤、髓母细胞瘤、视网膜母细胞瘤、肉瘤、脂肪肉瘤、滑膜细胞肉瘤、神经内分泌肿瘤、类癌肿瘤、胃泌素瘤、胰岛细胞癌、间皮瘤、神经鞘瘤、听神经瘤、脑膜瘤、腺癌、黑素瘤、白血病或淋巴样恶性肿瘤、鳞状细胞癌、上皮鳞状细胞癌、肺癌、小细胞肺癌、非小细胞肺癌、腺癌肺癌、肺鳞癌、腹膜癌、肝细胞癌、胃癌、肠癌、胰腺癌、成胶质细胞瘤、子***、卵巢癌、肝癌、膀胱癌、肝癌、乳腺癌、转移性乳腺癌、结肠癌、直肠癌、结肠直肠癌、子宫癌、唾液腺癌、肾癌、***癌、外阴癌、甲状腺癌、肝癌、***癌、***癌、梅克尔细胞癌、食管癌、胆道肿瘤、头颈部癌和血液恶性肿瘤。
23.根据权利要求21所述的应用,其特征在于,所述通式Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物单独使用,或与其它种类的药物制剂和/或治疗方法联合使用;
所述其他种类的药物制剂选自:PD-1、PD-L1、CTLA-4、TIM-3、TGF-β及其受体、LAG3拮抗剂或TLR4、TLR7、TLR8、TLR9、STING激动剂;
所述其他种类的治疗方法选自:放射疗法、免疫疗法。
24.一种权利要求1所述的通式为Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物在预防和/或治疗癌症、免疫疾病、炎症中的应用。
25.一种权利要求1所述的通式Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物联合PD-1、PD-L1、CTLA-4、TIM-3、TGF-β及其受体、LAG3拮抗剂或TLR4、TLR7、TLR8、TLR9、STING激动剂在癌症免疫疗法中的应用。
26.一种权利要求1所述的通式Ⅰ的化合物及其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物与CAR-T免疫疗法相结合在癌症免疫疗法中的应用。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2020355358A AU2020355358A1 (en) | 2019-09-25 | 2020-09-25 | PROTAC small molecule compound and application thereof |
PCT/CN2020/117573 WO2021057872A1 (zh) | 2019-09-25 | 2020-09-25 | 一种protac小分子化合物及其应用 |
EP20867475.4A EP4036093A1 (en) | 2019-09-25 | 2020-09-25 | Protac small molecule compound and application thereof |
JP2022519129A JP2022549871A (ja) | 2019-09-25 | 2020-09-25 | Protac小分子化合物及びその使用 |
US17/763,949 US20220331435A1 (en) | 2019-09-25 | 2020-09-25 | Protac small molecule compound and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910912417 | 2019-09-25 | ||
CN2019109124178 | 2019-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112552293A true CN112552293A (zh) | 2021-03-26 |
Family
ID=75041153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011016521.8A Pending CN112552293A (zh) | 2019-09-25 | 2020-09-24 | 一种protac小分子化合物及其应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220331435A1 (zh) |
EP (1) | EP4036093A1 (zh) |
JP (1) | JP2022549871A (zh) |
CN (1) | CN112552293A (zh) |
AU (1) | AU2020355358A1 (zh) |
WO (1) | WO2021057872A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114085215A (zh) * | 2021-11-15 | 2022-02-25 | 南方医科大学 | 一种富马酸酰胺类化合物或其药学上可接受的盐及其制备方法和应用 |
CN114349739A (zh) * | 2021-12-14 | 2022-04-15 | 杭州医学院 | 一种降解微管蛋白的偶氮类化合物及其合成方法和应用 |
US11878968B2 (en) | 2021-07-09 | 2024-01-23 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate IKZF2 |
WO2024027755A1 (zh) * | 2022-08-05 | 2024-02-08 | 杭州中美华东制药有限公司 | 一种protac嵌合化合物及其制备方法和用途 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
EP3873903B1 (en) | 2018-10-31 | 2024-01-24 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
WO2023023941A1 (en) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Hpk1 degraders, compositions comprising the hpki degrader, and methods of using the same |
WO2023097020A1 (en) * | 2021-11-23 | 2023-06-01 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as hpk1 degraders |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006021886A1 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
CN101023064A (zh) * | 2004-08-26 | 2007-08-22 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物 |
WO2011138751A2 (en) * | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
CN103265477A (zh) * | 2003-02-26 | 2013-08-28 | 苏根公司 | 作为蛋白激酶抑制剂的氨基杂芳基化合物 |
CN103965161A (zh) * | 2013-02-02 | 2014-08-06 | 正大天晴药业集团股份有限公司 | 取代的2-氨基吡啶类蛋白激酶抑制剂 |
CN104650049A (zh) * | 2013-08-28 | 2015-05-27 | 广东东阳光药业有限公司 | 取代的吡啶化合物及其使用方法和用途 |
WO2016161145A1 (en) * | 2015-03-31 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Stk4 inhibitors for treatment of hematologic malignancies |
CN107206088A (zh) * | 2014-12-05 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物 |
WO2018049152A1 (en) * | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
CN107922431A (zh) * | 2015-06-25 | 2018-04-17 | 大学健康网络 | Hpk1抑制剂及其使用方法 |
CN108366992A (zh) * | 2015-11-02 | 2018-08-03 | 耶鲁大学 | 蛋白水解靶向嵌合体化合物及其制备和应用方法 |
CN109152843A (zh) * | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
CN109912655A (zh) * | 2017-12-13 | 2019-06-21 | 上海科技大学 | Alk蛋白降解剂及其抗肿瘤应用 |
CN109923114A (zh) * | 2016-09-09 | 2019-06-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途 |
CN110204543A (zh) * | 2019-06-27 | 2019-09-06 | 江苏省中医药研究院 | 一种基于Cereblon配体诱导BET降解的吡咯并吡啶酮类双功能分子化合物 |
CN110234646A (zh) * | 2016-11-01 | 2019-09-13 | 阿尔维纳斯股份有限公司 | 靶向PROTAC的Tau蛋白及相关使用方法 |
CN110357889A (zh) * | 2018-04-09 | 2019-10-22 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
CN110396087A (zh) * | 2018-04-25 | 2019-11-01 | 珠海宇繁生物科技有限责任公司 | Hpk1激酶抑制剂、制备方法及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019206049A1 (en) * | 2018-04-25 | 2019-10-31 | Zhuhai Yufan Biotechnologies Co., Ltd | Hpk1 inhibitors, preparation method and application thereof |
-
2020
- 2020-09-24 CN CN202011016521.8A patent/CN112552293A/zh active Pending
- 2020-09-25 JP JP2022519129A patent/JP2022549871A/ja not_active Withdrawn
- 2020-09-25 AU AU2020355358A patent/AU2020355358A1/en active Pending
- 2020-09-25 WO PCT/CN2020/117573 patent/WO2021057872A1/zh unknown
- 2020-09-25 EP EP20867475.4A patent/EP4036093A1/en not_active Withdrawn
- 2020-09-25 US US17/763,949 patent/US20220331435A1/en active Pending
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103265477A (zh) * | 2003-02-26 | 2013-08-28 | 苏根公司 | 作为蛋白激酶抑制剂的氨基杂芳基化合物 |
CN101023064A (zh) * | 2004-08-26 | 2007-08-22 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物 |
WO2006021886A1 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
WO2011138751A2 (en) * | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
CN103965161A (zh) * | 2013-02-02 | 2014-08-06 | 正大天晴药业集团股份有限公司 | 取代的2-氨基吡啶类蛋白激酶抑制剂 |
CN104650049A (zh) * | 2013-08-28 | 2015-05-27 | 广东东阳光药业有限公司 | 取代的吡啶化合物及其使用方法和用途 |
CN107206088A (zh) * | 2014-12-05 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物 |
WO2016161145A1 (en) * | 2015-03-31 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Stk4 inhibitors for treatment of hematologic malignancies |
CN107922431A (zh) * | 2015-06-25 | 2018-04-17 | 大学健康网络 | Hpk1抑制剂及其使用方法 |
CN108366992A (zh) * | 2015-11-02 | 2018-08-03 | 耶鲁大学 | 蛋白水解靶向嵌合体化合物及其制备和应用方法 |
CN109152843A (zh) * | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
WO2018049152A1 (en) * | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
CN109923114A (zh) * | 2016-09-09 | 2019-06-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途 |
CN110234646A (zh) * | 2016-11-01 | 2019-09-13 | 阿尔维纳斯股份有限公司 | 靶向PROTAC的Tau蛋白及相关使用方法 |
CN109912655A (zh) * | 2017-12-13 | 2019-06-21 | 上海科技大学 | Alk蛋白降解剂及其抗肿瘤应用 |
CN110357889A (zh) * | 2018-04-09 | 2019-10-22 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
CN110396087A (zh) * | 2018-04-25 | 2019-11-01 | 珠海宇繁生物科技有限责任公司 | Hpk1激酶抑制剂、制备方法及其应用 |
CN110204543A (zh) * | 2019-06-27 | 2019-09-06 | 江苏省中医药研究院 | 一种基于Cereblon配体诱导BET降解的吡咯并吡啶酮类双功能分子化合物 |
Non-Patent Citations (2)
Title |
---|
S. KRAJCOVICOVA ET AL.: "Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC)", 《CHEM. COMMUN.》 * |
TRICIA L. MAY-DRACKA ET AL.: "Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11878968B2 (en) | 2021-07-09 | 2024-01-23 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate IKZF2 |
CN114085215A (zh) * | 2021-11-15 | 2022-02-25 | 南方医科大学 | 一种富马酸酰胺类化合物或其药学上可接受的盐及其制备方法和应用 |
CN114349739A (zh) * | 2021-12-14 | 2022-04-15 | 杭州医学院 | 一种降解微管蛋白的偶氮类化合物及其合成方法和应用 |
WO2024027755A1 (zh) * | 2022-08-05 | 2024-02-08 | 杭州中美华东制药有限公司 | 一种protac嵌合化合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
JP2022549871A (ja) | 2022-11-29 |
AU2020355358A1 (en) | 2022-04-28 |
WO2021057872A1 (zh) | 2021-04-01 |
US20220331435A1 (en) | 2022-10-20 |
EP4036093A1 (en) | 2022-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112552293A (zh) | 一种protac小分子化合物及其应用 | |
CN108699067A (zh) | 吡啶胺取代的杂三环化合物、其制法与医药上的用途 | |
JP2001139550A (ja) | アミド化合物の新規用途 | |
CN103476768A (zh) | 6,5-杂环炔丙醇化合物及其用途 | |
KR20050005548A (ko) | 치환된 3-아미노-티에노[2,3-b]피리딘-2-카복실산 아미드화합물 및 이의 제조방법 및 이의 용도 | |
CA3128416A1 (en) | Aromatic ring or heteroaromatic ring compounds, preparation method therefor and medical use thereof | |
AU2006298164A1 (en) | Novel fused pyrrole derivative | |
CN111936502A (zh) | 杂二环羧酸及其盐 | |
CN102762558A (zh) | 吡啶并吡啶酮衍生物、其制备及治疗用途 | |
JPH05230055A (ja) | 三環式ヘテロ環化合物、その製法及びこれを含有する抗−痛覚過敏作用を有する医薬組成物 | |
WO2002036583A1 (fr) | Compositions pharmaceutiques antagonistes du recepteur de pgd¿2? | |
WO2020020288A1 (zh) | 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途 | |
CN113518779B (zh) | 噻吩并杂环类衍生物、其制备方法及其在医药上的应用 | |
CN112300153A (zh) | 一种杂环化合物、药物组合物和用途 | |
TWI826535B (zh) | 環狀二核苷酸類似物、其藥物組合物及應用 | |
TWI243172B (en) | Heterocyclic derivatives and pharmaceutical use thereof | |
WO2022017408A1 (zh) | 芳胺类衍生物及其制备方法和医药用途 | |
WO2023143293A1 (zh) | 补体因子b抑制剂的盐型、晶型及其制备方法和应用 | |
KR20070029643A (ko) | IKK 억제제로서의 치환된3-아미노-티에노[2,3-b]피리딘-2-카복실산 아미드 화합물 | |
CN110835335B (zh) | 2,5-二酮哌嗪类化合物及其在制备抗癌药物中的应用 | |
WO2016026372A1 (zh) | 噻吩并环烷基或噻吩并杂环基类衍生物、其制备方法及其在医药上的应用 | |
WO2020029908A1 (zh) | 螺桥环化合物、其药物组合物及其用途 | |
WO2022089629A1 (zh) | 1,2,4-三氮唑衍生物及其制备方法和用途 | |
EP1776369A1 (en) | Thienopyridone carboxamides and their medical use | |
CN107793397B (zh) | 取代的嘧啶类pi3k抑制剂的光学异构体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210326 |
|
RJ01 | Rejection of invention patent application after publication |